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The first principle is that you must not fool yourself, and you are the easiest person to fool. 






POPULAR SCIENCE SUMMARY OF THE THESIS 
In healthy individuals, the liver only stores small amounts of fat. Alongside the surge of 
obesity and type 2 diabetes that have occurred over the past decades, the proportion of people 
who store large amounts of fat in their liver have increased dramatically. Today, up to a 
quarter of the global adult population have a condition called NAFLD, short for nonalcoholic 
fatty liver disease. The vast majority of individuals that have NAFLD do not experience any 
symptoms from the disease, but a subset of the patients goes on to develop inflammation and 
scarring in the liver tissue. While it is known that type 2 diabetes and NAFLD often co-exist, 
it is not clear how they interact. In its most severe form, NAFLD can lead to liver cirrhosis, 
impaired liver function and liver cancer. How to effectively identify the individuals with 
NAFLD and type 2 diabetes that are at the highest risk of developing severe liver disease is 
not known.  
In the first part of this doctoral thesis, we investigated which microscopic features in the liver 
tissue that are associated with an increased risk of type 2 diabetes in patients with NAFLD. 
We found that patients with NAFLD diagnosed on liver biopsy, where a small tissue sample 
is extracted from the liver and analyzed under a microscope, have a high risk of type 2 
diabetes. Higher level of scarring correlated to risk of type 2 diabetes. For patients with lower 
amounts of scarring, the amount of fat in the biopsy was associated with risk of type 2 
diabetes.  
In the second part, we used population-based registries to assess the risk of severe liver 
disease - such as failure of liver function or liver cancer - in patients with type 2 diabetes and 
found that the risk appears to be increased compared to individuals without diabetes. We also 
identified several risk factors in patients with type 2 diabetes that are associated with risk of 
severe liver disease. This can help to identify which patients with diabetes that could be 
considered for specific investigations of the liver to diagnose NAFLD and cirrhosis.  
In the third part, we examined a group of patients with type 2 diabetes that underwent a 
treatment program at a specialist clinic to achieve better control of their diabetes. The 
treatment program was a part of routine clinical care, and we studied how this treatment 
affected the liver health of the patients. Using a non-invasive technique called transient 
elastography, we found a high frequency of NAFLD and liver scarring in the patients with 
type 2 diabetes. We also found that the treatment program was associated with a reduced 
amount of fat in the patients with NAFLD after three months. 
In the fourth part, we again used population-based registries, and compared the risk of cancer 
in patients with NAFLD to the risk in individuals without NAFLD. We found NAFLD to be 
associated with a slightly increased risk of cancer in general. The strongest association was 
found between NAFLD and risk of the most common form of liver cancer, hepatocellular 
carcinoma. Patients with NAFLD had a slightly increased risk of bladder, kidney and uterine 
cancer. Further, male patients with NAFLD had a slightly increased risk of colorectal cancer.  
ABSTRACT 
The past decades have seen a marked increase in the incidence of type 2 diabetes and 
nonalcoholic fatty liver disease (NAFLD). Epidemiological studies have clearly demonstrated 
that there is an association between type 2 diabetes and NAFLD. Further, it has been 
established that patients with type 2 diabetes are at an increased risk of severe liver disease. 
While liver biopsy remains the gold standard for diagnosing NAFLD, it is not clear how - and 
if - the histological features of NAFLD are associated with an increased risk of type 2 
diabetes. It is unclear how to identify the subset of patients with type 2 diabetes that have the 
highest risk of severe liver disease. Likewise, it is not known how the currently practiced 
treatment strategies for type 2 diabetes affect the progression of NAFLD. Finally, the risk of 
cancer in the broader population of patients with NAFLD is not well known. 
In the first paper, we investigated the risk of type 2 diabetes in a cohort of patients with 
biopsy-proven NAFLD and found that higher stages of fibrosis were associated with an 
increased risk of type 2 diabetes. In patients with small amounts of fibrosis, the amount of 
steatosis on biopsy was associated with an increased risk of type 2 diabetes. These results 
indicate that fibrosis and simple steatosis are useful histological variables when estimating 
risk of type 2 diabetes in patients with NAFLD. 
In the second paper, we assessed the risk of severe liver disease (defined as a composite 
outcome of diagnoses correlated to cirrhosis) in a population-based cohort of patients with 
type 2 diabetes. We observed type 2 diabetes to be associated with an increased risk of severe 
liver disease compared to controls free of diabetes, and identified several risk factors for 
severe liver disease in patients with type 2 diabetes. These results motivate further studies to 
better characterize the patients with type 2 diabetes that are at a high risk of severe liver 
disease.  
In the third paper, we studied how a personalized 4-day treatment program for type 2 diabetes 
currently used in clinical practice at the Karolinska University Hospital in Stockholm affects 
the progression of NAFLD. Patients were examined with transient elastography at baseline 
and at a follow-up visit after three months. The prevalence of NAFLD and increased liver 
stiffness was high. Improved glycemic control seen after the treatment program was 
associated with a reduction in hepatic steatosis in patients with NAFLD at baseline. These 
results indicate that improving glycemic control in type 2 diabetes per se can also be effective 
in treating NAFLD. 
In the fourth paper, we examined the risk of cancer in a population-based cohort of patients 
with NAFLD compared to matched reference individuals. We observed an association 
between NAFLD and a slightly increased risk of any cancer. Of the specific types of cancer 
we investigated, the strongest association was found between NAFLD and risk of HCC. A 
slightly increased risk was also observed for bladder, kidney and uterine cancer. Further, 
male patients with NAFLD had a slightly increased risk of colorectal cancer. These results do 
not motivate general screening for cancer in patients with NAFLD.  
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In the recent decades, the incidence of type 2 diabetes and obesity have increased globally, 
with the worldwide prevalence of type 2 diabetes now estimated to around 8% (1, 2). With 
the development of both type 2 diabetes and obesity, various mechanisms lead to increased 
storage of fat in the liver, resulting in nonalcoholic fatty liver disease (NAFLD). Thus, 
alongside the increase in type 2 diabetes and obesity, an epidemic of NAFLD has emerged. In 
a meta-analysis from 2016 of 45 studies in which imaging techniques were used to diagnose 
NAFLD, Younossi and colleagues reported a global prevalence of 25% (3). The highest 
frequency was reported in two studies from South America (30%), and the lowest in two 
studies from Africa (13%). In Europe, Asia and North America, where a larger number of 
studies were available, a prevalence of 24%, 27% and 24% was reported, respectively. 
The liver does not physiologically store large amounts of fat, and the diagnostic threshold for 
NAFLD is presence of steatosis in ≥ 5% of hepatocytes on liver biopsy (4). For the diagnosis 
of NAFLD to be accurate, competing causes of liver disease such as excessive alcohol intake 
(≥20 g per day in women, ≥30 g per day in males), intake of medications with liver steatosis 
as a side effect, viral hepatitis and autoimmune liver disease need to be excluded (5). Among 
individuals with NAFLD, a subset have inflammatory changes in the liver tissue (4). This 
type of inflammatory damage, steatohepatitis, is highly similar to the pathologic finding 
induced by alcohol-related liver disease, and it wasn't until 1980 in a study by Ludwig and 
colleagues that the term nonalcoholic steatohepatitis (NASH) was coined (6). The 20 
individuals described in the study by Ludwig and colleagues had steatohepatitis in their liver 
tissue that occurred in the absence of excessive alcohol intake (6). A majority of the study 
participants, the authors noted, were obese and many of them had other pathologies related to 
obesity (6). As NASH is diagnosed by liver biopsy the true prevalence is somewhat difficult 
to approximate, but a widespread estimate is that around 20% of individuals who today have 
NAFLD also have NASH (7). A recent study from the United States by Harrison and 
colleagues reported the prevalence of NAFLD and NASH in a cohort of asymptomatic 
individuals referred for colonoscopy (8). In the study Harrison and colleagues, the study 
participants had a mean age of 56 years and a mean BMI of 30.5 kg/m2. Interestingly, 38% of 
the cohort had NAFLD (diagnosed by magnetic resonance imaging (MRI) proton density fat 
fraction), and 14% had NASH (diagnosed by liver biopsy).  Most commonly, NAFLD and 
NASH are seen as asymptomatic disorders as long as liver function is retained (9). However, 
in a study by Younossi and colleagues comparing patient reported outcomes between patients 
with NASH and patients with chronic hepatitis C infection, it was reported that patients with 
NASH had worse outcomes regarding fatigue, physical pain and vitality (10). While it is not 
clear that this observation was due to the NASH diagnosis per se, or due to other factors such 
as higher levels of obesity, the results from the study by Younossi and colleagues indicate 





Figure 1. Changes in etiologies of liver disease in the US relative to 1988-1994. From 
Younossi et al. Gut 2020 Mar;69(3):564-568. Published with permission. 
While liver biopsy remains the gold standard for diagnosing NAFLD, it can also be 
diagnosed using imaging techniques such as ultrasonography (US), MRI, magnetic resonance 
spectroscopy (MRS) and computed tomography (CT) (11). Liver enzymes, while commonly 
used in primary care settings, are however poor markers for the presence of NAFLD. In a 
2015 study by Portillo-Sanchez and colleagues, 103 patients with type 2 diabetes and normal 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT), without clinically 
significant chronic kidney disease or cardiovascular disease were examined with MRS to 
determine the prevalence of NAFLD and NASH (12). A NAFLD frequency of 50% was 
found, and out of the patients with NAFLD 56% had NASH, demonstrating the marked 
unreliability of liver enzymes for detection of NAFLD and NASH (12). 
Since the introduction of the term NASH, different scoring methodologies to define presence 
of NASH via assessing liver biopsies have been defined. One method, primarily constructed 
to function as a feasible outcome parameter in clinical trials, is the NAFLD activity score 
(NAS) proposed in a study by the NASH clinical research network in 2005 (4). The NAS 
system is based on scoring on the separate histological features: steatosis (stage 0-3), lobular 
inflammation (stage 0-3), and ballooning (stage 0-2). In all, the maximum score is 8. 
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Another standardized method for diagnosing NASH, called the Steatosis Activity Fibrosis 
(SAF) score, was first proposed in morbidly obese patients in 2012, and validated in 2014 in 
patients with metabolic syndrome (13, 14). In the SAF score, liver biopsies are graded on 
steatosis (scale 0-3), lobular inflammation (scale 0-2) and hepatocyte ballooning (scale 0-2), 
and a score of at least one in all three variables is necessary for a NASH diagnosis. 
Additionally, on liver biopsies, fibrosis is usually graded on a scale from 0-4 (4). It was 
recently reported that while all-cause mortality is increased in all patients with NAFLD, a 
gradual increase in risk is seen from simple steatosis, to NASH, to fibrosis, to cirrhosis 
(where scarring of the liver has become widespread, and liver function might decrease) (15). 
Transient elastography is an ultrasound based, non-invasive method where a probe is placed 
on the skin in the intercostal space over the liver. By generating a shear wave, the probe can 
produce a measurement of liver stiffness, expressed in kiloPascal (kPa). The kPa value can 
then be used as an indication of presence (or absence) of significant fibrosis. Further, the 
transient elastography can be used to estimate the controlled attenuation parameter (CAP), 
which provides an indication of the degree of hepatic steatosis (16).  
Figure 2. Schematic presentation of the transient elastography technique, where a probe is 
placed in the intercostal space to assess liver stiffness and steatosis. From Jaffer et al. 
Ultrasound. 2012;20(1):24-32. Published with permission. 
Since it is not feasible to perform a liver biopsy in all patients with NAFLD, several non-
invasive testing models for detecting advanced fibrosis in individuals with NAFLD have been 
developed (17). In general, the non-invasive models are characterized by high negative 
predictive value (NPV) and lower positive predictive value (PPV), hence limiting the clinical 
use to identifying patients eligible for referral to specialist centers and additional testing, 
rather than diagnosing advanced fibrosis (defined as stage 3-4 on biopsy) (17). A commonly 
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used non-invasive model to predict presence of advanced fibrosis is the fibrosis-4 (FIB-4) 
score. The FIB-4 score was initially developed to predict fibrosis in patients with co-infection 
of hepatitis C virus (HCV) and human immunodeficiency virus (HIV), and incorporates AST, 
ALT, platelets and age (18). In 2007, Angulo and colleagues proposed the NAFLD fibrosis 
score (NFS), which incorporates age, hyperglycemia/type 2 diabetes, body mass index 
(BMI), thrombocyte particle count, albumin and the ratio of AST to ALT, to non-invasively 
estimate the presence of advanced fibrosis (19). McPherson and colleagues published a study 
in 2010 where they tested the ability of different non-invasive models to predict advanced 
fibrosis in a cohort of 145 patients with biopsy-proven NAFLD, and found that the FIB-4 
score had a NPV of 95% and a PPV of 36% at a cut-off of 1.3 (17). In the same study, NFS 
was found to have a NPV of 92% and a PPV of 30% at a cut-off of -1.455 (17). Due to its 
comparable simplicity and repeatedly reported high NPV for advanced fibrosis, the FIB-4 
score has been proposed as a simple, first-stage screening tool for advanced fibrosis in 
primary care in recent studies (20). 
The causal mechanistic network involved in the development of NAFLD and NASH is 
complicated and not fully understood, but in principle consists of both lifestyle factors, such 
as high caloric intake from refined sugars also implicated in the pathogenesis of type 2 
diabetes and obesity, and genetic factors such as mutations in the patatin-like phospholipase 
domain-containing protein 3 gene (PNPLA3) and the transmembrane 6 superfamily 2 human 
gene (TM6SF2) (21-23). In a study published in 2008, Romeo and colleagues investigated 
the association between genetic variants and NAFLD in the Dallas Heart Study cohort (22). 
In 2011 individuals of varying ethnic descent they found the rs738409(G)-allele of the 
PNPLA3 gene to be associated with increased hepatic fat content, even after adjusting for 
confounders such as BMI, alcohol intake and diabetes (22). Interestingly, the rs738409(G)-
allele does not appear to be associated with other features of the metabolic syndrome, such as 
increased BMI, elevated triglycerides, low high density lipoprotein (HDL) or presence of 
type 2 diabetes (24, 25). On the other hand, the rs738409(G)-allele appears associated with an 
increased risk of development of hepatocellular carcinoma (HCC) caused by NAFLD, 
especially for homozygotic carriers (26). 
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Figure 3. The progression from normal glucose tolerance and normal liver, to NAFLD and 
type 2 diabetes. Abbreviations: NGT=normal glucose tolerance, T2D=type 2 diabetes, B-
cell=beta cell. From Gastaldelli et al. JHEP Rep 2019 Jul 19;1(4):312-328. doi: 
10.1016/j.jhepr.2019.07.002 https://creativecommons.org/licenses/by-nc-nd/4.0/. Published 
with permission. 
While a majority of patients with NAFLD are treated in primary care settings and not in 
specialized centers, the epidemics of NAFLD and NASH have been reported to be under-
recognized among both general practitioners and endocrinologists (27-30). In a study from 
the UK published in 2018, 133 healthcare professionals, mainly consulting endocrinologists 
and resident endocrinologists specializing in diabetes, were queried on their knowledge of 
NAFLD (29). A vast majority of the responders underestimated the prevalence of both 
NAFLD and NAFLD-related fibrosis in patients with type 2 diabetes (29). Further, a majority 
of the responders reported not having used any non-invasive scoring system, such as the FIB-
4 score, in the last year (29). In another study published in 2018, Australian researchers 
investigated the knowledge about NAFLD and NASH in primary health care professionals, 
mainly general practitioners, and found that half of them underestimated the prevalence of 
NAFLD in the general population to <10% (30). Additionally, a majority were uncertain 
about the clinical applicability of the FIB-4 score (30). In a recent study by Rashu and 
colleagues, the referral patterns to the Gastro Unit at the Copenhagen University hospital 
were studied. Of the 1 735 referred patients between January 2017 and June 2020, 323 
(18.6%) ended up receiving a diagnosis of NAFLD (31). Of the patients with NAFLD, a 
majority (62.5%) were referred from general practitioners. Though not all patients underwent 
liver biopsy, significant fibrosis (stage 2-4) was found in 71 (22% of referred patients with 
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NAFLD) of the 110 patients that were biopsied. At referral, the FIB-4 score had not been 
calculated in any of the patients (31). 
1.1 PATHOPHYSIOLOGICAL LINK BETWEEN TYPE 2 DIABETES AND NAFLD 
The pathophysiological interplay between type 2 diabetes and NAFLD is complex and 
involves several biochemical pathways and feedback loops, and it has been a longstanding 
question how the two disorders interact (32). In a study by Bugianesi and colleagues from 
2005, it was demonstrated that even non-diabetic, non-obese patients with NAFLD show 
signs of both hepatic and peripheral (both muscle and adipose tissue) insulin resistance 
compared to individuals without NAFLD (33). Likewise, it has been demonstrated that 
insulin resistance is an early detectable, independent predictor of impending development of 
type 2 diabetes (34). 
It has long been established that the association of increased fat deposits in the body and the 
risk of metabolic syndrome is dependent on the distribution of fat throughout the body. The 
tendency to store fat in the upper parts of the body, and especially in and around the visceral 
organs, is associated with a higher risk of developing the metabolic syndrome (35, 36). It has 
been proposed that this observation between visceral adiposity and an increase in risk of 
metabolic syndrome is due to an increased delivery of free fatty acids to the liver (37). In 
individuals without obesity, the proportion of free fatty acids (FFA) delivered to the 
hepatocytes of the liver coming from visceral fat stores is around 5-10%, whereas a larger 
part originates from subcutaneous adipose tissue. In individuals with visceral obesity, 
however, the proportion of FFA originating from visceral adipose tissue is around 30% (37). 
Animal models have shown that increased hepatic fat content, through diacylglycerol (DAG), 
can increase the activity of the enzyme protein kinase C epsilon (PKCε) (38). Once PKCε is 
activated it can impair insulin signaling in the hepatocyte by binding to and blocking the 
activity of the insulin receptor tyrosine kinase (38). Under normal physiological conditions, 
increased insulin signaling decrease gluconeogenesis in the liver and upregulate glycogen 
storage. When insulin action is inhibited, hepatocytes produce glucose in disproportionate 
amounts, resulting in hyperglycemia, initiating further increase in insulin production. In a 
2012 study by Magkos and colleagues of 16 obese humans, out of which 13 had NAFLD, 
intrahepatic DAG content was shown to positively correlate with degree of insulin resistance 
in the liver (39). 
The pathophysiological link between type 2 diabetes and NAFLD appears to be bidirectional 
in the sense that just as mechanisms by which increased fat content in the liver promotes 
insulin resistance have been described, a number of mechanisms by which elevated glucose 
and insulin levels over time can promote increased fat content in the liver have been proposed 
(40). When insulin production is increased in a person with insulin resistance, it can 
upregulate the activity of a transcription factor protein called sterol regulatory element-
binding protein 1 (SREBP-1) (41). Interestingly, SREBP-1 is upregulated via insulin receptor 
substrate-1 (IRS-1), which remains augmented even in insulin resistant hepatocytes of 
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patients with NAFLD, as opposed to IRS-2 which instead appears downregulated (41). When 
SREBP-1 is upregulated, it in turn upregulates the activity of Acetyl-CoA carboxylase (ACC) 
and fatty acid synthase (FAS), which are enzymes increasing de novo lipogenesis (DNL) 
(41). 
Figure 4. The pathophysiological interplay between NAFLD and type 2 diabetes. From 
Williams et al. Endocrine Review 2013 Feb;34(1):84-129. Published with permission. 
Increased glucose levels can increase the activity of an enzyme called xylulose-5-phosphate 
(Xu-5-P) (42). As Xu-5-P is upregulated, this in turn promotes activity of the protein 
phosphatase 2A (PP2A). The increased activity of PP2A leads to promotion of a transcription 
factor called carbohydrate responsive element binding protein (ChREBP) (42). By 
upregulation of genes that code for enzymes such as liver type pyruvate kinase, ACC and 
FAS, ChREBP promotes DNL (42). A further mechanism through which increased glucose 
levels can stimulate DNL is through by increasing the activity of nuclear receptor liver X 
receptor alpha (LXRα) (43). When activated, the LXRα stimulates activity in SREBP-1, ACC 
and FAS, resulting in increased DNL (40). 
1.2 RISK OF TYPE 2 DIABETES IN NAFLD 
Several epidemiological studies on the risk of development of type 2 diabetes in patients with 
NAFLD have been performed (44-63). Due to the different methods and criteria available to 
diagnose NAFLD and type 2 diabetes, a direct comparison between studies is complicated. 
Further, the commonly asymptomatic disease progression of both NAFLD and type 2 
diabetes often makes assessment of which of the two conditions that developed first difficult. 
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In one of the earliest studies of risk of type 2 diabetes in patients with NAFLD diagnosed by 
liver US, Okamoto and colleagues examined 840 individuals free of diabetes with liver US, 
and followed them for 10 years (44). At baseline, 120 of the 840 study participants were 
diagnosed with NAFLD. The authors reported an odds ratio (OR) of 2.62 (95% confidence 
interval [CI]=1.58-4.34) for a diagnosis of hyperglycemia at the 10-year follow-up visit in 
patients with NAFLD at baseline compared to individuals free of NAFLD (44). However, 
when adjusting for family history of diabetes, alcohol intake, frequency of medical check-
ups, hemoglobin A1c (HbA1c), fasting glucose, BMI and age, presence of fatty liver at 
baseline was not associated with an increased risk of hyperglycemia at follow-up (adjusted 
OR [aOR] 1.83, 95% CI=0.95-3.51). The finding that NAFLD was not independently 
associated with an increased risk of type 2 diabetes is in contrast with the vast majority of 
other studies testing the same hypothesis. This discrepancy is possibly explained by the 
relatively small sample size, leading to an underpowered study (44). 
In 2007, Shibata and colleagues investigated the risk of type 2 diabetes in 3 189 male workers 
older than 40 years from a company-based cohort in Japan (45). At baseline, 802 (25%) 
participants were diagnosed with NAFLD on liver US. During a mean follow-up of up 4 
years, 44 cases (1.8%) of type 2 diabetes occurred in the group without NAFLD at baseline, 
and 65 cases (8.1%) occurred in the group with NAFLD at baseline (45). Adjusted for age 
and BMI, the hazard ratio (HR) for development of type 2 diabetes in the NAFLD group 
compared to the non-NAFLD group was 5.5 (95% CI=3.6-8.5, p<0.001) (45). 
Several studies have reported that patients with more severe NAFLD appears to be at a 
greater risk of type 2 diabetes than do patients with less severe NAFLD. In a study from 
2008, Kim and colleagues examined 5 372 South Korean individuals with a mean age of 46.8 
years who underwent a routine health check-up, including liver US (46). At baseline, 1 790 
(33%) study participants had NAFLD. Over a follow-up of 5 years, 233 (4.3%) individuals 
developed type 2 diabetes and presence of NAFLD was associated with an increased relative 
risk (RR) of 1.51 (95% CI=1.04-2.20) for development of type 2 diabetes compared to 
individuals free of NAFLD (46). The patients with NAFLD were also divided into groups 
based on severity of NAFLD on liver US (mild, moderate or severe) (46). Interestingly, when 
excluding patients with excess alcohol intake and adjusting for sex, age, family history of 
diabetes, smoking, components of the metabolic syndrome and ALT, mild NAFLD was not 
associated with an increased risk of development of type 2 diabetes compared to individuals 
free of NAFLD (RR 1.49, 95% CI=0.82-2.71, p=0.19) (46). In the same analysis, moderate to 
severe NAFLD was associated with an increased risk of development of type 2 diabetes (RR 
2.29, 95% CI=1.13-4.63, p=0.02) (46). Similarly, in a 2013 study, Park and colleagues 
investigated the risk of type 2 diabetes in a cohort of over 25 000 men from South Korea, 
with a mean age of 42.5 years, who underwent a mandatory health check-up (47). At 
baseline, 8 858 (35%) patients had NAFLD. Over a mean follow-up of 3.7 years, 2 108 
(8.4%) participants developed type 2 diabetes (47). Adjusting for age, waist circumference, 
triglycerides, high density lipoprotein (HDL) cholesterol, systolic blood pressure, 
homeostatic model assessment of insulin resistance (HOMA-IR), C-reactive protein (CRP), 
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creatinine, family history of diabetes, exercise and metabolic syndrome, an increased risk of 
type 2 diabetes was found in patients with moderate to severe steatosis (aHR 1.73, 95% 
CI=1.00-3.01, p<0.001), but not in patients with mild steatosis (aHR, 1.09, 95% CI=0.81-
1.48), compared to individuals without NAFLD at baseline (47). 
The reduction of liver steatosis in patients with NAFLD has also been reported to associate 
with a decreased risk of development of type 2 diabetes (48). In a Japanese study of 3 074 
individuals examined with liver US, Yamazaki and colleagues examined the association 
between improvement of NAFLD and risk of development of type 2 diabetes (48). Of the 3 
074 participants included in the study, 728 (23.7%) had NAFLD at baseline. Over a mean 
follow-up of 11.3 years, 189 (6.1%) developed type 2 diabetes. Adjusted for age, BMI, 
exercise, family history of diabetes, impaired fasting glucose, hypertension and dyslipidemia, 
NAFLD was associated with an increased risk of development of type 2 diabetes (aOR 2.37, 
95% CI=1.60-3.52, p<0.001) (48). The increased risk of type 2 diabetes in patients with 
NAFLD was more pronounced in women (aOR 3.01, 95% CI=1.18-7.68) than in men (aOR 
2.27, 95% CI=1.47-3.51). Of the patients with NAFLD at baseline, 110 (15.1%) had reduced 
their amount of liver steatosis at the second examination. In multivariable regression adjusted 
for the above mentioned covariates, improvement of NAFLD was associated with a 
decreased risk of development of type 2 diabetes (aOR 0.27, 95% CI=0.12-0.61, p<0.01) 
compared to no improvement (48). 
In a study from 2017, using one of the larger cohorts ever examined when investigating the 
risk of type 2 diabetes in patients with NAFLD, Chen and colleagues reported findings from a 
study of 132 377 individuals examined with liver US (50). At baseline, 42 410 (32%) patients 
had NAFLD. Over a mean follow-up of 5.8 years, 6 555 individuals developed type 2 
diabetes. Adjusted for age ≥ 65 years, family history of diabetes, hypertension, BMI ≥ 27 
kg/m2, smoking, alcohol intake, physical activity, cholesterol, triglycerides, HDL, ALT, AST, 
gamma-glutamyltransferase (gamma-GT) and alkaline phosphatase (ALP), NAFLD was 
independently associated with an increased risk of development of type 2 diabetes (aHR 2.08, 
95% CI=1.93-2.23) (50). Further, ALT, AST, gamma-GT and ALP were also independently 
associated with an increased risk of development of type 2 diabetes (50). 
Summarizing 19 observational studies investigating the risk of type 2 diabetes in NAFLD, 
Mantovani and colleagues published a meta-analysis in 2018 (64). They included only studies 
that had used liver US or CT to diagnose NAFLD, and no studies with fewer participants than 
500 were included. In total, 296 439 individuals, out of which 30.1% had NAFLD, were 
included. Over a median follow-up of 5 years, 15 751 patients developed type 2 diabetes. In 
the pooled estimate of the HR for development of type 2 diabetes in patients with NAFLD 
compared to individuals without NAFLD, 16 studies were included (three were excluded due 
to no HR for type 2 diabetes in patients with NAFLD being reported) (64). After exclusion, 
four studies from China, four studies from Japan, four studies from South Korea, two studies 
from the US, one study from Taiwan and one study from Sri Lanka were included in the 
analysis. The pooled hazard ratio for development of type 2 diabetes in patients with NAFLD 
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compared to individuals without NAFLD was 2.22 (95% CI=1.84-2.60), though a substantial 
heterogeneity between studies (I2=79%) was reported (64). In a sensitivity analysis, using 
only the studies deemed to be of high-quality according to the Newcastle-Ottawa scale, ten 
studies were included and the resulting aHR was 1.85 (95% CI=1.47-2.22) (64). The 
heterogeneity between the high quality studies included in the sensitivity analysis (I2=68%) 
was, although still substantial, somewhat lower than the heterogeneity between the studies in 
the main analysis (I2=79%) (64). 
In 2006, Ekstedt and colleagues published a study where they examined 129 patients with 
biopsy proven NAFLD (65). The patients in the cohort had been referred to specialist centers 
due to persistently elevated liver enzymes. The mean follow-up was 13.7 years and the study 
cohort was compared to an age- and sex-matched background population. While 8.5% of the 
cohort had been diagnosed with diabetes before baseline, the authors were not able to 
ascertain baseline prevalence of type 2 diabetes as fasting glucose was not assessed at 
baseline. At the follow-up visit, 78% of the cohort had been diagnosed with either diabetes or 
impaired glucose tolerance. Interestingly, 71% of patients with NASH at baseline had been 
diagnosed with diabetes at the follow-up visit, while 46% of patients without NASH had 
diabetes at the follow-up visit (p=0.01) (65). 
In summary, hitherto performed studies have demonstrated an increased risk of type 2 
diabetes in patients with NAFLD. This increase in risk appears to be independent of other 
common risk factors, and a number of studies have reported an association between the 
severity of NAFLD and the magnitude of the increased risk of type 2 diabetes. Nonetheless, 
there’s a lack of studies investigating the risk of development of type 2 diabetes in patients 
with NAFLD using cohorts of patients with NAFLD who have been diagnosed using liver 
biopsy. While a large number of studies have been performed, a majority of them have had 
follow-up times ≤ 10 years, which is somewhat problematic as type 2 diabetes is highly 
correlated with aging. Indeed, the pathophysiological progression from obesity and increased 
ectopic fat accumulation, to emerging insulin resistance, to pre-diabetes with impaired 
glucose regulation, to a clinical diagnosis of type 2 diabetes can occur over decades. In 
addition, most studies have been done on cohorts from Asian populations. Hence, the 
potentially increased risk of type 2 diabetes in northern European populations with NAFLD 
have not been thoroughly investigated. 
1.3 RISK OF LIVER DISEASE IN TYPE 2 DIABETES 
Several studies have demonstrated that patients with type 2 diabetes have an increased risk of 
severe liver disease, such as HCC (66-70), cirrhosis (68-74), hepatic failure (74-76) and death 
from liver disease (77, 78). While other etiologies of HCC and cirrhosis such as excessive 
intake of alcohol and viral hepatitis are still major causes, NAFLD is now emerging as a 
frequent etiology of severe liver disease. Indeed, up to a third of all cases of HCC are today 
caused by metabolic disease (including NAFLD, obesity and type 2 diabetes), and NAFLD is 
projected to become the leading cause of liver transplantation in the coming decade in the US 
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(79-81). Likewise, liver transplantations due to NAFLD have increased in the Nordic 
countries during the last decades (82). 
In 2002, El-Serag and colleagues published a study where they examined the risk of acute 
hepatic failure (i.e. a rapid decrease of liver function occurring over days to weeks) in a 
cohort of military veterans in the United States (75). Using hospital registries, the authors 
identified 173 643 individuals with a discharge diagnosis of diabetes between 1985 and 1990 
and compared them to 650 620 individuals free of diabetes. The study participants were 
followed until 2001. No differentiation was made between patients with type 1 and type 2 
diabetes, and 98% of the individuals in the study cohort were male. Excluding patients with 
prior liver disease, including hepatitis B and C, and adjusting for age, sex, ethnicity, having 
served in the Vietnam war and comorbidities, the aHR for development of acute hepatic 
failure was 1.43 (95% CI=1.25-1.67) for patients with diabetes compared to individuals 
without diabetes (75). 
Investigating the leading causes of HCC in the US population, Welzel and colleagues 
published a study in 2013 on the population attributable fractions of HCC (81). Using data 
from insurance claims along with data from the United States National Cancer Institute, the 
authors identified 6 991 patients aged ≥68 years diagnosed with HCC in the US from 1994 to 
2007. Further, 255 792 reference individuals without HCC were included. While almost a 
third (31.2%) of the individuals who had developed HCC had a prior diagnosis of liver 
disease caused by alcohol, almost two thirds (61.5%) had a prior diagnosis of obesity and/or 
diabetes (81). Adjusting for viral hepatitis, alcohol-related liver disease, rare metabolic 
disorders, ethnicity and age, a diagnosis of obesity and/or diabetes was associated with HCC 
in both males (aOR 2.48, 95% CI=2.32-2.65) and females (aOR 2.43, 95% CI=2.21-2.66). 
The estimated population attributable fraction of obesity and diabetes for HCC was 36.6% 
(95% CI=34.6-38.6%). In a similar study from 2016, Makarova-Rusher and colleagues 
estimated the population attributable fractions of leading causes of HCC in the US (80). The 
authors combined diagnoses of NAFLD, obesity, metabolic syndrome, pre-diabetes and 
diabetes into one composite category representing risk factors related to the metabolic 
syndrome. Individuals aged ≥68 years diagnosed with HCC between 2000 and 2011 were 
included in the study. In total 10 708 patients with HCC and 332 107 reference individuals 
free of HCC were included (80). Adjusting for age, socioeconomic status, ethnicity, viral 
hepatitis, rare genetic disorders, alcohol-related conditions and smoking, the composite 
category of risk factors associated to the metabolic syndrome was associated with HCC in 
both males (aOR 2.8, 95% CI=2.6-2.9) and females (aOR 2.7, 95% CI=2.5-2.9). The 
estimated population attributable fraction of metabolic disorders for HCC was 32% (95% 
CI=30.5-33.5%) (80). 
Using the previously described cohort of military veterans, El-Serag and colleagues published 
a study in 2004 where they examined the risk of chronic liver disease and HCC in individuals 
with diabetes (66). Excluding patients with hepatitis C and B, and adjusting for age, sex, 
having served in the Vietnam war and comorbidities, the aHR for development of chronic 
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nonalcoholic liver disease including cirrhosis was 1.98 (95% CI=1.88-2.09) for patients with 
diabetes compared to individuals free of diabetes. Adjusting for the same variables, the 
hazard ratio for development of HCC was 2.13 (95% CI=1.79-2.53) for patients with diabetes 
(66). 
In a study published in 2016, Wild and colleagues compared the incidence of liver disease in 
patients with type 2 diabetes to that of individuals free of diabetes (67). They used the 
Scottish National Diabetes Registry along with the Scottish hospital admission records, 
cancer records and causes of death records to ascertain cases of liver disease (67). Cases of 
alcoholic liver disease, autoimmune liver disease, haemochromatosis, HCC, NAFLD and 
viral hepatitis were ascertained during 1.8 million person years in patients with type 2 
diabetes and during 24 million person years in individuals free of diabetes (67). The reported 
rate ratio, adjusted for age and socio-economic status, for HCC in patients with type 2 
diabetes compared to individuals free of diabetes was 3.36 (95% CI=2.97-3.81) in men and 
3.55 (95% CI=3.02-4.17) in women. In the same study, the authors reported a rate ratio of 
NAFLD in patients with type 2 diabetes compared to individuals free of diabetes of 3.03 for 
men and 5.11 for women (67). However, while a NAFLD-diagnosis per se most often does 
not represent a clinically significant liver disease and might be an “innocent bystander” in 
patients hospitalized for cardiovascular disease or diabetes, international classification of 
diseases (ICD) codes for more severe forms of liver disease, such as cirrhosis and portal 
hypertension were included in the NAFLD-category of ICD codes, rendering the results 
somewhat difficult to interpret (67). 
Summarizing studies of how components of the metabolic syndrome affect the risk of severe 
liver disease, Jarvis and colleagues published a meta-analysis of 18 studies in 2020 (83). In 
the analysis of risk of severe liver disease in patients with type 2 diabetes, 12 studies were 
included. In total, 22.8 million individuals with a median follow-up of 10 years were 
included. Combining studies on both fatal and non-fatal severe liver disease in individuals 
with no other liver disease etiology than NAFLD, type 2 diabetes was associated with an 
increased risk of severe liver disease (HR 2.25, 95%=1.83-2.76). It should be noted that the 
heterogeneity between included studies was considerable (I2=99%) (83). 
Due to the poor sensitivity of blood tests for aminotransferases for detecting NAFLD, a very 
large proportion of patients with type 2 diabetes and concurrent NAFLD are not diagnosed 
with NAFLD in the routine clinical practice (12). Examining the prevalence of NAFLD and 
cirrhosis in a Chilean cohort of patients with type 2 diabetes and no known liver disease, 
Arab and colleagues published a study in 2016 (84). Individuals with other causes of liver 
disease than NAFLD were excluded. In total, 133 participants older than 55 years, with a 
mean BMI of 29.6 kg/m2 were included in the study and underwent MRI. Around two thirds 
(64%) of the cohort had findings of steatosis on MRI, and 6% had findings indicative of 
cirrhosis on MRI. Using the NFS to estimate presence of fibrosis, the authors found evidence 
of advanced fibrosis in 13% of the cohort (84). 
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A number of studies have investigated the use of transient elastography to detect NAFLD and 
elevated liver stiffness in patients with type 2 diabetes (85-93). Kwok and colleagues 
published a study in 2016 where they performed transient elastography on 1 918 patients with 
type 2 diabetes (86). Study participants were included at a specialist center in Hong Kong 
where patients underwent screening for complications of type 2 diabetes, and individuals with 
other liver disease than NAFLD were excluded. Cut-offs used to ascertain steatosis were 222-
232 dB/m for steatosis grade 1 (S1), 233-289 dB/m for S2 and ≥290 dB/m for S3. To 
ascertain fibrosis stage 3 (F3) a liver stiffness measurement (LSM) of 9.6 kPa was used, and 
for F4 a LSM of ≥11.5 kPa. On average, participants were aged 61 years and their average 
BMI was 26.6 kg/m2. Of 1 799 patients with sufficient quality for steatosis measurements, 
73% had S1 or higher. Of 1 884 patients with sufficient quality LSM, 334 (18%) had values 
indicating at least advanced fibrosis (≥F3), of which 224 patients (12%) had kPa values 
indicating cirrhosis. In total, 94 patients, of which 74% had LSM indicating advanced fibrosis 
or cirrhosis, went on to have a liver biopsy. The PPV and NPV of the transient elastography 
to detect advanced fibrosis or cirrhosis were 59% and 84%, respectively (86). 
The studies on risk of severe liver disease in patients with type 2 diabetes that have been 
conducted so far have had some methodological problems that limits implementation of 
generated findings into clinical care. In many earlier studies, differentiation between type 1 
and type 2 diabetes was not possible. Since patients with type 1 diabetes have a lower risk of 
severe liver disease than patients with type 2 diabetes, the risk-estimates are likely falsely low 
in studies that have included both patients with type 1 and type 2 diabetes. Further, study 
cohorts have in many instances been rather selected, for example including a majority of male 
participants, and have not been population based. The outcomes of interest in many studies 
have either been specific diagnoses of severe liver disease (for example cirrhosis), mortality 
from specific diagnoses (for example mortality from cirrhosis), or a combination of severe 
liver disease and early stage, less clinically relevant liver disease. Finally, there is a lack of 
studies investigating risk factors for severe liver disease in patients with type 2 diabetes. 
Thus, interpreting results from previous studies with regards to the population-based risk of 
severe liver disease in general in patients with type 2 diabetes is somewhat difficult. 
1.4 RISK OF CANCER IN NAFLD 
Given the local effect of hepatic fat accumulation and subsequent inflammatory damage to 
the hepatic tissue, it is not surprising that an association between NAFLD and an increased 
risk of HCC has been reported across a number of studies (94-97). Further, the risk of several 
other forms of cancers, such as colorectal (98-104), bladder (105) and breast cancer (106-
108) in patients with NAFLD have also been examined. 
To investigate the risk of HCC in patients with NAFLD, Younossi and colleagues examined 
cases of HCC occurring from 2004 to 2009 in the United States. Individuals with HCC were 
identified using data from the National Cancer Institute and Medicare insurance claims (97). 
The database used contained data on cancer incidence in 28% of the United States 
population. Of the 4 979 cases of HCC included in the study, 701 occurred in individuals 
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with NAFLD. As controls, 14 937 individuals (1 243 with NAFLD) without HCC were 
included, out of which 83% had no known liver disease. Adjusting for sex, ethnicity and 
comorbidities, NAFLD was associated with HCC (aOR 2.62, 95% CI=2.28-3.00) (97). 
Assessing the risk of HCC in patients with NAFLD, Kanwal and colleagues published a 
study in 2018 (96). The authors included patients diagnosed with NAFLD from 2004 to 2008 
in healthcare facilities organized by the Veterans Health Administration. Study participants 
were considered as having NAFLD if competing causes of hepatic steatosis were lacking, and 
their ALT levels were ≥ 40 IU/ml for men and ≥ 31 IU/ml for women on at least two separate 
occasions with at least 6 months having passed in between. In total, 296 707 individuals with 
NAFLD, and the same number of controls free of NAFLD matched for sex and age, were 
included in the study. Due to participants being included from the Veterans Health 
Administration, 94.4% of the cohort were men. Over a mean follow-up of 9 years, 490 
patients with NAFLD and 55 controls developed HCC. In a multivariable analysis adjusted 
for age, ethnicity, BMI, diabetes and hypertension, NAFLD was associated with risk of HCC 
(aHR 7.62, 95% CI=5.76-10.09, p<0.01). Study participants with NAFLD but no cirrhosis 
had an incidence rate (IR) of HCC of 0.08 cases per 1000 person-years, whereas participants 
with NAFLD and cirrhosis had an IR of 10.6 cases per 1000 person-years. Thus, the absolute 
risk of HCC in patients with NAFLD without cirrhosis was low (96). 
The risk of colorectal cancer in patients with NAFLD was investigated in a 2011 study by 
Stadlmayr and colleagues (98). Including individuals who underwent routine screening with 
colonoscopy for colorectal cancer at a single center in Austria between 2007 and 2009, the 
authors compared the prevalence of colorectal cancer in 632 patients with NAFLD compared 
to 579 individuals free of NAFLD. Excluding patients with liver disease other than NAFLD, 
and individuals with excess alcohol consumption, NAFLD was diagnosed liver US. 
Colorectal cancers were significantly more common in male patients with NAFLD (1.6%) 
than in males free of NAFLD (0.4%), whereas no significant difference was found in 
females. In a logistic regression analysis adjusted for impaired glucose regulation, BMI, age 
and sex, NAFLD was independently associated with presence of colorectal adenomas (OR 
1.47, 95% CI=1.08-2.00, p=0.02) (98). 
In a study published by Lin and colleagues in 2014, the authors examined the association 
between NAFLD and prevalence of colorectal cancer in a Chinese community cohort (101). 
Individuals were excluded if they had other liver disease than NAFLD, and NAFLD was 
diagnosed using liver US. After exclusion, 2 315 study participants, of which 263 had 
NAFLD, were included. The study participants with NAFLD had a significantly higher 
prevalence (29.3%) of colorectal cancer than the individuals free of NAFLD (18%). In a 
logistic regression analysis adjusted for several important confounders including BMI, blood 
lipids, and liver blood markers, NAFLD was independently associated with colorectal cancer 
(aOR 1.87, 95% CI=1.36-2.57, p<0.01) (101). 
Examining the risk of colorectal adenomas and colorectal cancer in patients with NAFLD, 
Mantovani and colleagues published a systematic review and meta-analysis of 11 studies in 
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2018 (64). The authors included studies of 300 or more participants, and only studies on 
asymptomatic individuals undergoing screening colonoscopy. Only studies where NAFLD 
was diagnosed using liver biopsy (one study) or some form of imaging technique (ten studies) 
were included, and both cross-sectional and longitudinal studies were included. Of the 11 
studies analyzed, eight were cross-sectional and three were longitudinal. Five studies were 
performed on South Korean cohorts, four were performed on Chinese cohorts, one was 
performed on an Austrian cohort and one was performed on a Taiwanese cohort (64). The 
prevalence of NAFLD in the included cohorts ranged from 11.4% to 45.7%. In total, 91 124 
individuals were included in the meta-analysis, out of which 32.1% had NAFLD. All 
included studies performed regression analyses adjusted for several confounders, and a 
majority adjusted for important confounders such as smoking, BMI and diabetes. In the 
combined analysis of cross-sectional studies where NAFLD was diagnosed using radiology, 
NAFLD was associated with an increased prevalence of colorectal cancer (aOR 1.56, 95% 
CI=1.25-1.94). Likewise, in the one study where NAFLD was diagnosed using liver biopsy, 
an association with colorectal cancer was found (aOR 3.04, 95% CI=1.29-7.18). One 
longitudinal study included in the meta-analysis investigated risk of incident colorectal 
cancer, and found NAFLD to be independently associated with risk of colorectal cancer (aHR 
3.08, 95% CI=1.02-9.03) (64). This longitudinal study, however, was performed on a cohort 
consisting only of females, and had a relatively short mean follow-up of 4.5 (64). 
Studying the risk of several extrahepatic cancers in patients with NAFLD, Allen and 
colleagues published a study on a community based cohort of 4 772 patients with NAFLD 
and 14 441 reference individuals matched for age and sex (95). An increased risk of 
colorectal cancer was found in male patients with NAFLD compared to reference individuals 
(incidence rate ratio (IRR) 2.4, 95% CI=1.6-3.9). No increased risk of colorectal cancer was 
found, however, in female patients with NAFLD compared to reference individuals (IRR 1.3, 
95% CI=0.8-2.1) (95). The authors further examined how NAFLD interacts with obesity 
regarding risk of cancer and reported that while an increase in risk was observed in patients 
with NAFLD compared to both non-obese (IRR 2.0, 95% CI=1.5-2.9) and obese controls 
(IRR 2.0, 95% CI=1.5-2.7) without a diagnosis of NAFLD, no increased risk was observed in 
obese patients without a diagnosis of NAFLD compared to non-obese controls (IRR 1.0, 95% 
CI=0.8-1.4. One interpretation of these results could be that further research should test the 
hypothesis that NAFLD is a driver of the generally increased risk of cancer in the obese 
population, but residual confounding cannot be ruled out partly due to the register-based 
nature of the study.  
The research on the risk of breast cancer in patients with NAFLD has been performed 
primarily in the last five years. In 2017, Nseir and colleagues published a study where they 
investigated the results of examinations undertaken at mammography screening center in 
Israel from 2008 to 2011 (106). To assess the frequency of NAFLD, the authors used the 
results from abdominal CT-scans performed within one month after the diagnosis of breast 
cancer. Individuals matched for age and BMI who underwent mammography and breast US 
with normal results and performed an abdominal CT-scan within three months, were used as 
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controls. In total, 73 patients with breast cancer and 73 controls were included. No significant 
differences in age, BMI, smoking, diabetes or metabolic syndrome were found between cases 
and controls. Adjusting for age > 25 years at first delivery and use of estrogen, NAFLD was 
associated with an increased risk for breast cancer (aOR 2.82, 95% CI=1.20-5.50, p=0.02) 
(106). 
Following a cohort of individuals who had underwent a health check-up at a hospital in South 
Korea from 2004 to 2005, Kim and colleagues investigated the risk of breast cancer in 11 981 
women (94). Around one fifth (21%) of the women included in the cohort had NAFLD 
(diagnosed with liver US) at baseline and study participants were followed for a median of 
7.5 years. Patients who developed cancer within one year of their health check-up were not 
included in the study. After adjusting for smoking, sex, diabetes, hypertension, gamma-GT, 
LDL and HDL cholesterol and triglycerides, NAFLD was associated with an increased risk 
of developing breast cancer (aHR 1.92, 95% CI=1.15-3.20, p=0.01) (94). In the same study 
by Kim and colleagues, the authors also reported associations between NAFLD and risk of 
HCC (aHR 16.73, 95% CI=2.09-133.85, p<0.01). Further, an association between NAFLD 
and risk of colorectal cancer was reported in males (aHR 2.01, 95% CI=1.10-3.68, p=0.02), 
but not in females (aHR 0.63, 95% CI=0.21-1.89, p=0.41). No association was found 
between NAFLD and gastric cancer. 
In a case-control study published in 2019, Kwak and colleagues examined the association 
between NAFLD and risk of breast cancer in 270 patients with breast cancer and 270 controls 
(107). Study participants (both cases and controls) were included from 2008 to 2017 while 
undergoing a voluntary health check-up at a hospital in South Korea. The health check-up 
included both liver US and mammography. In addition to excluding patients with competing 
causes of liver steatosis, individuals aged younger than 30 years and patients with previous 
breast cancer were excluded. Controls were matched to cases on age and BMI. Among cases, 
30% had NAFLD, and among the controls 20% had NAFLD. In a multivariable logistic 
regression model adjusted for age at menarche, blood pressure, triglycerides, gamma-GT, 
metabolic syndrome, waist circumference and BMI, NAFLD was associated with breast 
cancer (aOR 1.63, 95% CI=1.01-2.62, p=0.046). The authors further investigated the 
association between NAFLD and breast cancer after stratifying the cohort on obesity (BMI ≥ 
25 kg/m2). Interestingly, NAFLD was associated with breast cancer in the fully adjusted 
model for the non-obese patients (aOR 3.04, 95% CI=1.37-4.32, p<0.01), but not for the 
obese patients (aOR 0.40, 95% CI=0.11-1.45, p=0.16) (107). 
In a recent study by Simon and colleagues, the risk of cancer in Swedish patients with biopsy-
proven NAFLD was investigated (109). All patients in Sweden who had received a diagnosis 
of NAFLD confirmed by biopsy between 1966 and 2016 were included. During a median 
follow-up of 13.8 years, a total of 1 691 cases of cancers were identified in 8 892 included 
patients with NAFLD. For each patient with NAFLD, at least five reference individuals 
without a diagnosis of NAFLD from the general population were included. The reference 
individuals were matched to NAFLD patients on age, sex, calendar year and county of 
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residence. A total of 6 733 cases of cancer were observed in the 39 907 reference individuals. 
Adjusting for alcohol abuse (as a time-varying covariate), cardiovascular disease, diabetes, 
hypertension, dyslipidemia, hypertension, obesity, end-stage renal disease, family history of 
cancer (younger than 50 years), number of hospital visits and level of education, an 
association with an increased risk of any cancer (aHR 1.27, 95% CI=1.18-1.36) was found in 
patients with NAFLD compared to reference individuals. The association between NAFLD 
and an increased risk of cancer was found across the spectrum of disease severity in patients 
with NAFLD and simple steatosis, NASH but no fibrosis, fibrosis but no cirrhosis, and 
cirrhosis. While the increase in risk of cancer in patients with NAFLD appeared largely 
driven by the association to risk of HCC (aHR 17.08, 95% CI=11.56-25.25), an association 
between NAFLD and risk of extra-hepatic solid organ cancer was also observed (aHR 1.12, 
95% CI=1.04-1.20). A limitation of the study is that liver biopsy is seldom performed in 
NAFLD. Hence, some degree of selection bias is likely present.  
Taken together, studies performed to test the hypotheses of an association between NAFLD 
and an increased risk of development of cancer indicate that this association does exist, and 
that it is primarily driven by an increased risk of HCC in patients with NAFLD compared to 
individuals without NAFLD. Regarding the risk of other common cancers in patients with 
NAFLD, the observed results vary between different studies. This variation likely stems from 
methodological differences. For example, the way to define a diagnosis of NAFLD differ 
between studies, ranging from use of non-invasive models incorporating BMI and blood 
markers, to liver US, to liver biopsy. In the studies investigating cohorts were NAFLD have 
been defined using less sensitive diagnostic modalities, such as liver transaminases, the 
estimated prevalence of NAFLD is likely falsely low. In the studies investigating cohorts 
where NAFLD have been identified by liver biopsy, one can expect the patient population to 
be rather selected and likely to include more severe cases of NAFLD. Thus, the capture rate 
of the exposure is bound to differ between the different studies, rendering comparison of 
results difficult. Further, the characteristics of the cohorts - and the information on important 
confounders in the studied cohorts - vary between studies. Some of the largest studies have 
been done on selected cohorts that are not derived from population-based databases, lowering 
the external validity. 
1.5 TREATMENT OF NAFLD 
Due to the strong association between obesity and NAFLD, weight loss has been examined as 
a possible treatment for NAFLD. In a study by Vilar-Gomez and colleagues, 293 patients 
with biopsy-proven NASH undertook a one-year life-style intervention where they were 
instructed to reduce their caloric intake to 750 kcals lower than their daily need of energy 
(110). Further, 200 minutes/week of walking was recommended. On average, study 
participants lost 4.6kg (SD +/-3.2kg). At the end of the study a new biopsy was performed, 
where 25% of study participants were free of NASH, and the degree of weight loss was 
independently associated with histological improvement (110). 
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Different macronutrient compositions in diets have been studied in patients with NAFLD 
(111-116). In 2011, Haufe and colleagues published a study where they compared the effects 
of calorie restricted low-carbohydrate and low-fat diets on 170 overweight and obese subjects 
(111). Over a period of six months, 102 patients completed the study protocol where their 
baseline energy intake was lowered by 30%. The subjects were instructed to consume ≤90 
grams of carbohydrates/day in the low-carbohydrate group, and fat equaling to ≤20% of total 
energy intake in the low-fat group. Both groups saw similar relative reductions in hepatic fat 
content; -47% for the low carbohydrate group, and -42% for the low fat group with a non-
significant difference between groups (111). A mechanism by which the low-carbohydrate, 
ketogenic diet can reduce hepatic fat content in spite of an increase in circulating fatty acids 
was proposed in a 2020 study by Luukkonen and colleagues (115). In the study, 10 obese or 
overweight individuals consumed a hypocaloric ketogenic diet (≤25 grams/day) for 6 days. 
The diet resulted in an increased hepatic insulin sensitivity, a reduction in circulating insulin 
and an increase in the breakdown of hepatic fat to be used for ketone production (115). The 
effect of intermittent calorie restriction and a low-carbohydrate diet on NAFLD compared to 
standard treatment was tested in a recent study by Holmer and colleagues (116). In total, 74 
patients with NAFLD were randomized to reduced caloric intake two days per week (600 
kilo calories/day for men and 500 kilo calories/day for women), a low-carbohydrate high-fat 
diet (less than 10% from carbohydrates and up to 80% from fat), or standard of care (which 
included recommendations on reduced intake of saturated fat and sweets) for 12 weeks. Both 
the intermittent calorie restriction diet (-6.1%) and the low-carbohydrate high-fat diet (-7.2%) 
generated a larger absolute reduction in hepatic steatosis than the standard of care treatment (-
3.6%). The average relative reductions in hepatic steatosis were -16.8% for participants 
randomized to standard of care, -50.9% for participants randomized to intermittent calorie 
restriction, and -53.1% for participants randomized to the low-carbohydrate high-fat diet. 
(116). 
The effects of different types of exercise and respiratory fitness on NAFLD and NASH have 
also been studied. In a 2009 study from Australia, St George and colleagues published a 
study where 141 patients with NAFLD were assigned to a low intensity lifestyle intervention, 
a moderate intensity lifestyle intervention or a control group during three months (117). As a 
marker for improvement of NAFLD, the authors used liver enzymes. The patients who were 
physically active achieved an improvement in their liver enzymes compared to individuals 
who were sedentary (117). In 2011, Hallsworth and colleagues studied the effects of an eight-
week training program focused on resistance exercise in 11 patients with NAFLD compared 
to ten patients with NAFLD who underwent no training program. Amount of intrahepatic fat 
was ascertained using MRS. After eight weeks, the intervention group achieved a relative 
reduction in liver fat content of 13% (p=0.01). Interestingly, this reduction in liver fat was 
achieved in absence of significant reductions in BMI or total body fat mass (118). 
While no medication has yet been approved for the treatment of NAFLD, several substances 
have been investigated. Due to the commonalities between type 2 diabetes and NAFLD it has 
been hypothesized that various forms of anti-diabetic medications could be effective in 
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treating NAFLD, and several studies have examined this hypothesis in the past couple of 
decades (119-139).   
In one of the earliest randomized controlled trials of the insulin sensitizer thiazolidinedione in 
patients with NASH and type 2 diabetes or impaired glucose tolerance, Belfort and 
colleagues compared the effect of six months of treatment with Pioglitazone with placebo 
(120). In total, 55 patients were randomized to receive either treatment or placebo. All study 
participants underwent liver biopsy to diagnose NASH, MRI to assess amount of hepatic 
steatosis and an oral glucose tolerance test to ascertain type 2 diabetes or impaired glucose 
tolerance. In addition to receiving either placebo or 45 mg of Pioglitazone per day, all 
subjects were instructed to lower their daily caloric intake by 500 kilo calories. At the end of 
the treatment period, participants who received Pioglitazone had gained on average 2.5 kg's, 
compared to a reduction of on average 0.5 kg's in the placebo group. Liver fat content 
measured by MRS reduced on average 54% in the treatment group, while it did not change in 
the placebo group. The Pioglitazone treatment was associated with improvement in histologic 
markers of necroinflammation, but not with reduced fibrosis (120). While some subsequent 
trials of thiazolidinediones have shown reduction in fibrosis (121, 130), others have shown 
improvements in steatosis, but not in fibrosis (122, 124, 125). In a study by Bril and 
colleagues, an association between treatment with thiazolidinedione and reduction in fibrosis 
was observed in patients with type 2 diabetes, but not in patients with pre-diabetes (139). 
There are, however, concerns about the side effects of thiazolidinediones, which limits their 
clinical applicability (140). 
To examine the effect of the glucagon like peptide (GLP)-1 analogue Liraglutide on NAFLD, 
Armstrong and colleagues enrolled 52 patients with biopsy-proven NASH across four centers 
in the UK in a study published in 2016. The study participants were randomized to 48 weeks 
of treatment with Liraglutide or placebo. The treatment was significantly associated with 
resolution of NASH, but not with improvement of fibrosis. There was, however, a significant 
association between treatment with Liraglutide and no progression of fibrosis (131). In a 
recent study of the effect of the GLP-1 analogue Dulaglutide on hepatic fat content in patients 
with NAFLD and type 2 diabetes, Kuchay and colleagues randomized 64 patients to either 24 
weeks with Dulaglutide or continued standard of care (137). Liver fat was measured using 
MRI, and liver stiffness was assessed using transient elastography. A significant association 
between treatment with Dulaglutide and reduction in liver fat was reported, but no association 
with reduction in liver stiffness was observed (137). In a phase 2 trial published in 2021, 
Newsome and colleagues randomized 320 patients with NASH to receive either placebo, or 
daily Semaglutide treatment of either 0.1 mg, 0.2 mg or 0.4 mg for 72 weeks (141). In the 
group that received the 0.4 mg dose 59% achieved resolution of NASH, whereas 33% in the 
placebo group achieved resolution of NASH (p<0.001). No significant difference between 
treatment and placebo groups were found regarding improvement of fibrosis (141). 
The effect of the sodium glucose co-transporter 2 (SGLT2) inhibitor Dapafliglozin on hepatic 
steatosis and liver stiffness assessed by transient elastography was investigated in a study by 
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Shimizu and colleagues published in 2019 (136). In total, 63 participants with NAFLD and 
type 2 diabetes were randomized to either Dapafliglozin or continued standard of care for 24 
weeks. The authors used a LSM cut-off of ≥8 kPa to indicate fibrosis. At the end of the study, 
treatment with Dapafliglozin was significantly associated with reduced CAP (reflecting 
hepatic steatosis), but not with a reduction in LSM (reflecting hepatic fibrosis) (136). 
The results from the studies on treatment of NAFLD indicate that what was previously 
known to lower the risk of other diseases related to the metabolic syndrome - weight loss and 
to some degree exercise - is also effective in treating NAFLD. Unfortunately, sustainable 
weight loss is difficult to achieve for most patients. Alternative paths to treating NAFLD 
should therefore be explored. The studies on treatment of NAFLD with different anti-diabetic 
agents show some promise. Several studies indicate that agents such as SGLT-2 inhibitors 
and GLP-1 analogues can reduce hepatic steatosis. The effects on fibrosis and long term 
severe liver disease, however, remain unclear. Due to the fact that a majority of patients with 
type 2 diabetes have NAFLD, and that type 2 diabetes is a risk factor for more severe disease 
progression in NAFLD, it is of clinical importance to understand how the modern-day 
treatment strategies for improving type 2 diabetes affects the progression NAFLD. This is, 




2 RESEARCH AIMS 
The aims of this doctoral thesis were to: 
1. Investigate the incidence of type 2 diabetes in a cohort of patients with biopsy-proven 
NAFLD and examine if any histological characteristics associate with risk of development of 
type 2 diabetes (study 1). 
2. Examine the risk of severe liver disease in patients with type 2 diabetes compared to 
controls free of diabetes, and to identify risk factors associated with development of severe 
liver disease (study 2). 
3. Investigate the prevalence of NAFLD and increased liver stiffness in patients with type 2 
diabetes, and to assess the effects of a personalized treatment program to improve glycemic 
control on liver health (study 3). 
4. Study the risk of cancer in patients with NAFLD compared to individuals free of NAFLD 




3 MATERIALS AND METHODS 
3.1 STUDY DESIGN 
In study 1, we assessed the risk of type 2 diabetes in patients with NAFLD. Participants were 
included from a cohort of patients with retrospectively collected data, who had been 
examined with liver biopsy at Karolinska University Hospital from 1971 to 2009. The 
indication for performing liver biopsies on patients in this cohort was predominantly a finding 
of persistently elevated liver transaminases. At baseline, the patients included also had 
metabolic parameters such as fasting glucose, blood lipids, blood pressure and BMI 
documented. All individuals with type 2 diabetes at baseline were excluded. For a patient to 
be classified as having type 2 diabetes, a diagnosis had to be present in the medical chart or in 
the NPR (defined as an ICD-code of E11), or a prescription of oral anti-diabetic medications 
or insulin had to be present in the patients’ medical chart. The liver biopsies were all re-
evaluated by one pathologist who assessed the quality of the biopsies and scored them to 
identify NASH (according to the SAF score) and fibrosis (as described by Kleiner and 
colleagues)(4, 13). The outcome of interest, development of type 2 diabetes, was identified 
through manual review of participants’ medical charts. For individuals who had migrated 
from Stockholm we could not access their medical charts, hence the National Patient Registry 
(NPR) was used to identify diagnoses of type 2 diabetes. The NPR contains information on 
diagnoses for all patients admitted to hospitals in Sweden have received since 1964 and has a 
PPV for the majority of chronic disease between 85% and 95%. Further, it includes 
information on all diagnoses patients have received in out-patient visit in specialized care 
since 2001. Study participants were followed up until February 20, 2016. 
In study 2, we examined the risk of severe liver disease in patients with type 2 diabetes. The 
National Diabetes Registry (NDR) was used to assemble the cohort. In the NDR, Swedish 
patients with diabetes are documented. Coverage has increased throughout the last decades to 
the point where the registry now includes the majority (around 90%) of patients with diabetes 
in Sweden. When a patient is included in the NDR, healthcare personnel documents 
information on metabolic parameters, anthropometric variables and medications. All 
individuals above 18 years of age with type 2 diabetes registered in the NDR between 1998 
and 2012, without pre-existing liver disease - other than NAFLD - were included in the study. 
Other pre-existing liver disease than NAFLD were excluded through identification of 
relevant ICD-codes in the NPR. We defined all patients in the NDR with dietary treatment 
(with or without antidiabetic oral medication) and all patients older than 39 years when they 
were first diagnosed with diabetes as having type 2 diabetes. As controls free of diabetes, five 
individuals from the background population, matched for age, sex and living location were 
obtained from Statistics Sweden and included in the study. Baseline data on metabolic 
parameters, anthropometric variables and medications were not available for the reference 
individuals. The outcome of interest in study was severe liver disease. We chose to construct 
a composite outcome variable representing severe liver disease, including cirrhosis, 
decompensation events, hepatic failure, liver transplantation, HCC and death from any of 
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these diagnoses. The combination of several liver-related severe outcomes into one composite 
outcome variable was done because we thought the implications from our results for the 
clinical management of patients with type 2 diabetes would be more impactful with the 
combined outcome than if we had chosen to analyze separate severe liver-related diagnoses 
as main outcomes. This approach was also recently recommended by a large international 
panel of experts (142). As secondary outcomes, development of HCC and death from liver 
disease were analyzed separately. Outcomes were ascertained through the NPR, the Causes of 
Death Registry (CDR) and the Swedish Cancer Registry (SCR). The CDR documents the 
cause of death for all citizens of Sweden since 1961, and the SCR was established in 1958, 
and cover approximately 96% of all cancer cases in Sweden. Study participants were 
followed up until December 31, 2014. 
In study 3, we investigated the effects of measures taken to improve the glycemic control in 
patients with type 2 diabetes on their liver health. To assemble the cohort for study 3, we 
invited patients with type 2 diabetes who were attending a 4-day treatment program at the 
endocrinology clinic at the Karolinska University Hospital. Individuals lacking understanding 
of the Swedish language were not considered for participation in the study as informed 
consent required sufficient skills in the Swedish language. Moreover, patients with a co-
existing liver disease or those who had previously undergone a liver transplantation were 
excluded. All individuals who attend the program have been referred by their general 
practitioner due to difficulties managing the patient’s glycemic control at the primary care 
level, or some other component of the patient’s metabolic health, such as blood pressure or 
kidney damage, being difficult to manage. The treatment program is comprised of different 
measures aimed at improving the glycemic control and associated metabolic parameters. In 
addition to individual consultations by an endocrinologist, participants in the program are 
offered lectures by an endocrinologist, a specialist nurse and a dietician. Further, a seminar 
with a physiotherapist is included. At the start of the week, all patients were invited to 
participate in our study. At inclusion, baseline blood markers reflecting liver health and 
metabolic status were collected, other markers of metabolic health (e.g. blood pressure, BMI, 
waist-to-hip ratio) were documented, and a transient elastography examination to identify 
steatosis and increased liver stiffness was performed. To assess the effect of the treatment 
program on the liver health of the study participants, all patients were invited to a follow-up 
visit at approximately three months after the baseline examination. We chose the time period 
of three months as we deemed this an appropriate time interval for assessing effects of 
implemented lifestyle changes. At the follow-up visit, a second transient elastography 
examination was performed, and all markers of metabolic and liver health documented at 
baseline were collected again. 
In study 4, we evaluated the risk of cancer in patients with NAFLD. The cohort was 
constructed from identification of all patients above 18 years of age, without any prior 
diagnosis of cancer, who received a code for NAFLD in the NPR (ICD-9: 578.1, ICD-10: 
K75.8 or K76.0) between January 1, 1987 and December 31, 2016. As controls, up to 10 
reference individuals matched for age, sex and living location were obtained from Statistics 
 
 25 
Sweden and included in the study. The primary outcome of interest, any cancer (except non-
melanoma skin cancer), was identified through the SCR. Secondary outcomes were HCC, 
colorectal, stomach, kidney, bladder, cervix, ovary, uterus, breast, lung and esophagus cancer. 
Outcomes were identified from one year after baseline up until December 31, 2016. Thus, 
cancers that occurred earlier than one year after baseline were not counted as outcomes. The 
reason for introducing a one year-lag on the identification of the outcome was that we were 
interested in the effect of NAFLD on the risk of development of cancer. The lag was thought 
to mitigate the risk that the cancer, while undiagnosed, had actually been present in the study 
participant before baseline. 
As excess accumulation of fat in the liver can result from multiple different causes, the 
diagnosis of NAFLD is ascertained when competing causes such as over-consumption of 
alcohol or intake of medications known to cause liver steatosis have been ruled out. This can 
be difficult to achieve as many real world patients have for example a condition of co-
existing obesity and excess consumption of alcohol, which both contributes to development 
of liver steatosis. This problem is also present when trying to construct a cohort of patients 
with "true" diagnoses of NAFLD. In studies 1 and 3, participants with competing causes of 
liver disease were excluded by manual review of medical charts and by questionnaires, and in 
all patients in study 3 specifically by blood sampling of phosphatidylethanol. In studies 2 and 
4, exclusions were based on presence of a diagnosis of a competing cause in the population-
based registries. 
3.2 STATISTICS 
In studies 1, 3 and 4 we used Fisher’s exact test and Wilcoxon rank sum test to investigate the 
differences between baseline variables of the different groups of the cohorts. To assess the 
association between baseline variables and risk of development of type 2 diabetes, we used a 
Cox regression model in study 1. The cohort was also divided into patients with or without 
advanced fibrosis at baseline. This was done as the risk of mortality is higher in patients with 
significant fibrosis, which in turn would've rendered the results difficult to interpret had all 
patients in the cohort been included in the same Cox regression model.  
In study 2, Cox regressions were used for different purposes. First, the risk of development of 
the main outcome (severe liver disease) and secondary outcomes (HCC and death from 
severe liver disease) were compared between patients with type 2 diabetes and controls from 
the general population. As the controls were matched on sex, age and living location, and no 
other baseline variables were known regarding the controls, the Cox regression was 
univariable. Second, including only patients with type 2 diabetes, for whom several baseline 
variables were available, a Cox regression was performed to investigate which variables were 
associated with an increased risk of severe liver disease. Initially, univariable models were 
constructed for each baseline variable, where after a multivariable model where all baseline 
variables were included was constructed. In study 3, we used linear regression to investigate 
if any associations between the primary outcomes (liver steatosis and stiffness) and other 
parameters were present. As we were interested in evaluating a potential change in liver 
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steatosis and stiffness occurring from baseline (before the intervention program) to follow-up 
(three months after the intervention program), we used delta values (i.e. the change from 
baseline to follow-up visits) in the linear regression. The linear regression thus generated a 
beta-value, representing the change in liver steatosis and/or liver stiffness per change in other 
parameters, and an adjusted R2-value, representing how much of the change in the outcome 
of interest is predicted by the other parameter. Further, as we were also interested in assessing 
the applicability of the FIB-4 score in this cohort, we calculated the sensitivity and specificity 
of the FIB-4 score for presence of elevated liver stiffness at baseline. To assess the broader 
clinical implications of the intervention program, differences between baseline and follow-up 
in parameters reflecting the metabolic health of the study participants were evaluated with 
Fisher’s exact test for categorical variables and Wilcoxon ranksum test for continuous 
variables. 
In study 4, we performed Cox regression analyses to assess the association between the 
exposure (NAFLD) and primary (any cancer excepts non-melanoma skin cancer) and 
secondary outcomes (specific cancers specified above). As we did obtain information 
regarding some co-morbidities chosen to reflect the metabolic health of study participants as 
well as information regarding presence of chronic obstructive pulmonary disease (as a proxy 
for smoking), we calculated both non-adjusted and adjusted risk estimates. Owing to previous 
studies having reported a difference in the association between NAFLD and risk of cancers in 
male and female subjects, we performed Cox regression analyses stratified on sex for the 
cancers where an association with NAFLD was observed in the main analysis. 
3.2.1 SENSITIVITY ANALYSES 
Sensitivity analyses were conducted in all studies. These were performed to test if any of the 
main analyses performed in our different studies contained biases which would be exposed 
when applying different criteria for the construction of the models. 
In study 1, we performed two kinds of sensitivity analyses. First, the risk of development of 
type 2 diabetes was compared between groups of patients based on presence of NASH and 
fibrosis, where the group with no fibrosis and no NASH was used as reference. Second, we 
performed the same calculation of risk estimates as in the main analysis while excluding 
study participants where the NPR had been used to identify presence of type 2 diabetes. This 
was done to assess whether the inclusion of data from the NPR skewed the results in the main 
analysis. 
In study 2, we performed a sensitivity analysis where all participants with a duration of 
follow-up under 1 year were excluded. This analysis was performed to assess whether 
individuals who had an outcome identified before 1 year of follow-up (and possibly had 
started developing severe liver disease before their diagnosis of type 2 diabetes) significantly 
altered the results in the main analysis. To assess how the risk of severe liver disease varies 
across different age groups of patients with type 2 diabetes, we performed the main analysis 
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separately in age-stratified groups of patients, ranging from under 40 years all the way up to 
above 80 years in 10-year strata, thus producing six different age groups. 
In study 3, we performed a sensitivity analysis including only patients who had been 
examined with the same size of transient elastography probe at baseline and follow-up visits 
(and not, for example, the medium sized probe at the baseline visit and the extra-large sized 
probe at the follow-up visit). We did this to examine if use of different probes at baseline and 
follow-up introduced an inconsistency in measurement results which might have affected the 
main analysis. 
In study 4, we performed one sensitivity analysis restricted only to patients who did not have 
a diagnosis of cirrhosis at baseline. This was done as previous studies had indicated that 
presence (or absence) of cirrhosis could be of great importance in assessing the risk of cancer 
in patients with NAFLD. In a second sensitivity analysis, we were interested in finding out if 
a potentially increased risk of the combined outcome of any cancer in individuals with 
NAFLD was primarily due to an increased risk of HCC specifically. To examine this, we 
performed an analysis where the only cancer cases we included were participants who did not 
have a diagnosis of HCC as their first cancer. In a third analysis, we examined whether a 
possible increased risk of development of HCC during follow-up in patients with NAFLD but 
no cirrhosis at baseline was influenced by that they might have developed cirrhosis during 
follow-up. To assess this, we included only participants that did not develop cirrhosis during 
follow-up. Further, we aimed to investigate if the probable increased risk of overall mortality 
in patients with NAFLD would influence the estimates of cumulative incidence from our Cox 
regression analysis. One method to approach this problem is by performing a competing risk 
analysis. Thus, we applied a competing risk regression where the competing risk event was 
death from other causes than cancer. 
3.3 ETHICAL CONSIDERATIONS 
In all scientific research, especially research involving animals or humans, careful 
consideration has to be given to potentially harmful effect of performing experiments or 
observations. Moreover, one needs to consider the implications of the results that might be 
produced, in that the conclusions drawn from generated results might impact the world 
outside the context of scientific research. While we performed blood tests and transient 
elastography examinations on the patients in the third study, we did not expose participants to 
any type of experimental treatment in our studies. Nonetheless several ethical questions need 
to be considered in the studies we've performed. In studies 1, 2 and 4, we included data from 
patients who were deceased, which can pose an ethical dilemma. Individuals who are still 
alive can, if they for example consider registry-based research unethical, try to persuade 
policy makers and build public opinion against the allowance of this type of research. 
Deceased individuals obviously can no longer voice their opinion and try to influence policy 
makers regarding participating in the study. However, never including deceased patients in 
studies would render testing of hypotheses involving mortality impossible, and the potential 
future benefits of preventing premature death would be lost. Thus, we argue that the benefits 
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of studying the disease course of deceased individuals outweigh the negatives. When we 
included data from population-based registries, we did not ask each participant for consent to 
participate in the study. Studying individuals without their consent also poses a clear ethical 
dilemma. Asking each individual in a population-based registry (many times covering 
millions of patients) for their consent regarding participation in a study would, however, 
demand enormous resources and render epidemiologic studies on such large cohorts 
practically impossible. As no intervention is performed on a patient that is included in a 
registry-based study, the risk for the patient can be considered to be largely related to 
questions of personal integrity. Thus, proper management of patient data to avoid harm to 
personal integrity is a crucial part of registry-based research and which we strictly adhered to 
in these studies. On the patients we studied in the clinic, in study 3, we performed an 
examination on their liver (transient elastography) and took blood tests that they otherwise 
would not have been exposed to, had they not participated in the study. Even if the patients 
who did have elevated liver stiffness did benefit from finding this out, it could be argued that 
the examinations were not performed in line with evidence based standards and routine 
clinical management, and therefore was not in the best interest of the patients, but rather an 
experimental practice in our scientific pursuit of falsifying a hypothesis. However, all patients 
gave written informed consent to participate after reading a clear description of the study. The 
line between routine medical practice and scientific endeavors needs to be clear. While many 
patients are well informed, their conceptual understanding of the aim and importance of 
participating in a study comes from physician who is also acting as a clinical researcher. 
Therefore, striving for objectiveness and clear communication about the aims of performing 





4.1 STUDY 1 
In study 1, a total of 396 patients with biopsy-proven NAFLD were included and followed for 
a median of 18.4 years. One third of the cohort (n=132, 33%) developed type 2 diabetes 
during follow-up. Comparing the group that developed type 2 diabetes during follow-up to 
the group that did not, we found a number of differing baseline variables. At baseline, the 
group that developed type 2 diabetes during follow-up had a statistically significant (p<0.05) 
higher proportion of individuals with hypertension (34.8% vs 20.8%) and a higher proportion 
of individuals with advanced fibrosis (stage 3-4) than the group that did not develop type 2 
diabetes (15.2% vs 7.2%).  
 
Table 1. Baseline characteristics of the cohort in study 1.  
Variable Developed T2DM 
(N=132) 
Free of T2DM 
(N=264) 
   








0.44 396 (100) 
Age (years) 47.4 12.0 45.0 14.4 0.11 396 (100) 






0.92 352 (88.9) 
Follow-up time 
(years) 







<0.001 381 (96.2) 
BMI (kg/m2) 28.1 3.8 27.3 4.2 0.03 379 (95.7) 
Thrombocytes 
(109/L) 
247.4 64.7 260.7 82.2 0.23 323 (81.6) 
Haemoglobin 
(g/dL) 
14.9 1.2 14.8 1.2 0.39 377 (95.2) 
WBC (109/L) 6.8 1.8 6.7 2.1 0.46 324 (81.8) 
Ferritin (μg/L) 248.8 167.7 235.2 218.5 0.18 187 (47.2) 
ALT (U/L) 131.1 523.1 114.3 400.3 0.87 392 (99.0) 
AST (U/L) 73.3 249.2 63.6 170.4 0.68 389 (98.2) 
ɣGT (U/L) 109.7 143.7 110.8 124.5 0.53 332 (83.8) 
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Bilirubin (μmol/L) 0.7 0.5 0.7 0.5 0.48 367 (92.7) 
Albumin (g/dL) 4.3 0.5 4.2 0.4 0.02 344 (86.9) 
Cholesterol 
(mmol/L) 







0.03 251 (63.4) 
Glucose (mg/dL) 96.2 17.5 94.5 17.9 0.37 307 (77.5) 




0.22 396 (100) 
NAS (0-8) 4.7 1.85 4.4 2.0 0.10 396 (100) 






<0.001 396 (100) 
Table 1. Baseline characteristics of the cohort in study 1. Abbreviations: ALT= alanine 
aminotransferase; AST= aspartate aminotransferase; γGT=gamma-glutamyltransferase; 
SD=standard deviation; WBC=white blood cells. 
 
Mean baseline values of BMI (28.1 vs 27.3 kg/m2) and albumin (4.3 vs 4.2 g/dL) were higher 
in the group that developed type 2 diabetes than in the group that did not. Further, the 
proportion of patients with triglycerides higher than 150 mg/dL at baseline was significantly 
higher (45.5% vs 33%) in the group that developed type 2 diabetes than in the group that did 
not. In the group of patients with advanced fibrosis (stage 3-4) at baseline, 51.2% developed 
type 2 diabetes during follow-up, while 31.3% of the group of patients with fibrosis stage 0-2 
developed type 2 diabetes. Adjusting for age, BMI, sex and triglycerides >150 mg/dL, fat 
score on biopsy was associated with risk of development of type 2 diabetes during follow-up 
(aHR 1.36, 95% CI 1.03-1.79, p=0.03) for patients with fibrosis stage 0-2. In the same model, 
no associations were found for NASH or scores for ballooning, inflammation or NAS.  
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Figure 5. Kaplan-Meier curve for risk of type 2 diabetes in patients with fibrosis stage 0–2, 
stratified by histologic fat score of 1 vs 2–3. Log-rank < .001. Published with permission. 
No associations between development of type 2 diabetes and histological markers were found 
in the group of patients with advanced fibrosis at baseline. The group with advanced fibrosis 
was more likely to die during follow-up, with 25.6% dying in the group with fibrosis stage 0-
2, and 55.9% dying in the group with advanced fibrosis. In the sensitivity analysis evaluating 
the risk of development of type 2 diabetes in patients with NASH and no fibrosis, NASH and 
fibrosis stage 1-2, and NASH and fibrosis stage 3-4 compared to the group of patients with 
simple steatosis and no fibrosis, we found that only the group with NASH and fibrosis stage 
1-2 had an increased risk in the fully adjusted model. Of note, the group with advanced 
fibrosis lacked data on baseline levels of triglycerides, which was included in the fully 
adjusted model, in 51.2% of patients. In the model adjusted for age, BMI and sex, the group 
with advanced fibrosis had an increased risk compared to the group with simple steatosis and 
no fibrosis (aHR 3.07, 95% CI=1.35-6.96, p<0.01). 
4.2 STUDY 2 
In study 2, we included 406 770 patients with type 2 diabetes who were followed for a 
median of 7.7 years. On average, the patients with type 2 diabetes were overweight, with a 
mean BMI of 29.8 kg/m2, and just over half the group were men (53.8%). Hypertension was 
present in 61.7%, and 12.1% were smokers. Close to one in five (19.0%) were on insulin 
treatment, and 52.5% were on anti-diabetic oral medication at the start of the study. Baseline 
microalbuminuria and macroalbuminuria was present in 8.6% and 4.7% of patients, 
respectively. A little more than 1% (5092 individuals, 1.3%) of patients with type 2 diabetes 
developed the main outcome, severe liver disease, before the end of the study. As reference 
individuals free of diabetes, we included 2 033 850 controls matched for age, sex and living 
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location. Other baseline variables were not obtained for reference individuals. Severe liver 
disease occurred in 11 619 (0.6%) of controls during follow-up. Type 2 diabetes was 
associated with an increased risk (HR 2.28, 95% CI=2.21-2.36, p<0.01) of severe liver 
disease compared to not having diabetes. Similarly, type 2 diabetes was associated with an 
increased risk of both secondary outcomes, development of HCC (HR 3.18, 95% CI=2.94-
3.44) as well as dying from severe liver disease (HR 2.29, 95% CI=2.17-2.41, p<0.01), 
compared to not having diabetes. While an increased risk of severe liver disease across all 
age groups of patients with type 2 diabetes compared to their respective reference individuals 
was found, differences were observed in the absolute risks between the different age groups. 
In the group under 40 years, and the 40-49-year group, the proportion of patients with type 2 
diabetes who developed severe liver disease was 0.18% and 0.56%, respectively. In the 50-
59-year group, the proportion of patients with type 2 diabetes who developed severe liver 
disease was 1.08%, increasing with age to 1.39% in the 60-69-year group, to 1.62% in the 70-
79-year group. 
 
Table 2. Risk factors for severe liver disease in patients with type 2 diabetes in study 2. 















































































Table 2. Risk factors for severe liver disease in patients with type 2 diabetes in study 2. Cox 
regression models were performed to estimate hazard ratios. The multivariable model is 
adjusted for all other variables. Abbreviations: aHR=adjusted hazard ratio; BMI=body mass 
index; CI=confidence interval; DBP=diastolic blood pressure; GFR=glomerular filtration 
rate; HbA1c=glycosylated hemoglobin; HDL=high-density lipoprotein; HR=hazard ratio; 
LDL=low-density lipoprotein; SBP=systolic blood pressure; T2DM=type 2 diabetes mellitus. 
Published with permission. 
 
In the multivariable Cox regression analysis of risk factors for severe liver disease performed 
separately in patients with type 2 diabetes, we found several baseline variables to be 
significantly associated with an increased risk: age (aHR 1.05, 95% CI=1.05-1.06), smoking 
(aHR 1.58, 95% CI=1.35-1.86), BMI (aHR 1.04, 95% CI=1.02-1.05), GFR (aHR 1.01, 95% 
CI=1.00-1.01) and microalbuminuria (aHR 1.25, 95% CI=1.01-1.45)). In the sensitivity 
analysis where we wanted to examine if patients having severe liver disease diagnosed during 
the first year of follow-up influenced the results in the main analysis, and therefore excluded 
these individuals, we obtained similar results as in the main analysis. 
4.3 STUDY 3 
After excluding patients who were previously liver transplanted, who had excessive alcohol 
intake, who were not fluent in Swedish, and patients with unreliable transient elastography 
examinations, 91 participants were enrolled in study 3 (flowchart in Figure 6). The study 
cohort had a majority of male participants (58%) and a median age of 59 years. Median 
baseline levels of HbA1c and BMI was 71 mmol/mol and 30.1 kg/m2, respectively. Baseline 
hypertension was present in 69.2% of the cohort, while 63.7% were on statin treatment, 
61.5% were on insulin treatment, 73.6% were on metformin treatment, 15.4% were on GLP-
1-analogue treatment and 6.6% were on SGLT-2-inhibitor treatment at baseline. Due to 
technical difficulties performing the transient elastography exam and due to the 
malfunctioning of the software on the machine used to perform the transient elastographies, 
reliable data on liver steatosis and liver stiffness could not be obtained in all enrolled 
individuals at baseline or follow-up. At baseline, 76% of patients with reliable steatosis 
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measurements had results indicating presence of NAFLD (CAP >268 dB/m), and 24.2% had 
results indicating presence of significant fibrosis (kPa >7.9). Stiffness levels signifying 
advanced fibrosis (> 13.9 kPa), were found in 8.8% of patients at baseline. Of the 91 patients 
enrolled at baseline, 13 individuals chose not to participate at the follow-up examination. 
Over the course of the study, reductions in steatosis were seen in 64% of participants with 
CAP values that indicated NAFLD at baseline, and in which reliable CAP values were 
obtained at follow-up (n=39). This translated into an average decrease of 18.3 dB/m in 
patients with NAFLD at the start of the study. Similarly, 67% of participants with elevated 
liver stiffness at baseline and reliable stiffness measurements at follow-up (n=15) achieved a 
decrease in liver stiffness during the study. An average decrease in liver stiffness of 2.6 kPa 
was observed during the course of the study in participants where an increased liver stiffness 
was recorded at the start of the study. 
Figure 6. Flowchart for patients included in study 3. 
We found that improvement in fasting glucose from baseline to follow-up was associated 
with improvement in steatosis in patients with NAFLD in linear regression. The reduction in 
CAP per one unit mg/dl reduction in fasting glucose, or beta, was 0.48 dB/m. The R2 value, 
denoting the proportion of change in CAP that could be ascribed to changes in fasting 
glucose, was 0.35. This association was stable after adjusting for changes in BMI and if 
patients had been started on treatment with GLP-analogues during the intervention week 
(beta=0.45 dB/m, R2=0.41). Further, the association remained in the sensitivity analysis 
including only patients who had been examined with the same size of probes at both study 
visits.  
 
Table 3. FIB-4 score as a predictor of elevated liver stiffness at baseline in study 3. 
 
≥8 kPa <8 kPa  
Intermediate or high FIB-4 7 6 PPV 54% 
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Low FIB-4 14 58 NPV 81% 
 Sensitivity 33% Specificity 91%  
Table 3. Sensitivity, specificity, PPV and NPV of the FIB-4 score for elevated liver stiffness 
measurement on transient elastography in study 3. Abbreviations: FIB-4=fibrosis 4 score, 
kPa=kilopascal, NPV=negative predictive value, PPV=positive predictive value. 
 
Regarding changes in liver stiffness, we found no association with changes in other variables. 
In the calculations of the PPV and NPV of the FIB-4 score regarding prediction of increased 
liver stiffness (defined as a value of ≥8 kPa), we found a PPV of 54% and a NPV of 81% 
4.4 STUDY 4 
In the fourth study, we included 8 415 patients with an ICD-based diagnosis of NAFLD, 
without a previous diagnosis of cancer. As in study 3, the study cohort had a slight majority 
of male patients (56%). In addition to the patients with NAFLD, we included 70 934 controls 
matched for age, sex and county. The median age of the study participants was 53 years. 
Close to one fifth (19.1%) of patients with NAFLD had a recorded diagnosis of diabetes, one 
fourth (25.6%) had hypertension, one tenth had hyperlipidemia (11.1%) and one in thirty had 
COPD (3.3%) at baseline. In reference individuals, co-morbidities were less common, with 
3.4% having diabetes, 7.4% having hypertension, 2.5% having hyperlipidemia and 0.9% 
having COPD at baseline.  
Over the course of the study (median follow-up 6.0 years), we observed 527 occurrences of 
cancer in the NAFLD group (6.3%, incidence rate [IR] 9.7 per 1000 person-years), while 
4716 (6.6%, IR 8.6 per 1000 person-years) cases occurred in the control group. Both the 
analysis in which patients with cirrhosis at baseline (n=183) were excluded and the analysis 
where additional patients who obtained a diagnosis of cirrhosis during the study (n=10) 
period were excluded generated results where an association between NAFLD and risk of 
HCC was observed. 
 
Table 4. Baseline characteristics of the cohort in study 4  



















54 (23) 53 
(23) 
p<0.01 62 (12) 54 (24) p<0.01 
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p<0.01 81 (44.3) 4490 (54.5) p<0.01 
Baseline 
comorbidities 
     
Cirrhosis, n (%) 183 (2.2) 0 (0.0) - 183 (100) - - 




p<0.01 105 (57.4) 1502 (18.2) p<0.01 
COPD, n (%) 280 (3.3) 614 
(0.9) 







p<0.01 85 (46.4) 2086 (25.3) p<0.01 
Hyperlipidemia, 
n (%) 
937 (11.1) 1 804 
(2.5) 
p<0.01 35 (19.1) 902 (11.0) p<0.01 
Liver biopsy 
within 1 year 
prior to baseline, 
n (%) 
481 (5.7) 2 (0.0) p<0.01 24 (13.1) 457 (5.6) p<0.01 
Year of diagnosis      
1987-1989, n (%) 160 (1.9) - - 3 (1.6) 157 (1.9) p=1.00 
1990-1999, n (%) 397 (4.7) - - 4 (2.2) 393 (4.8) p=0.11 
2000-2009, n (%) 2 298 
(27.3) 
- - 31 (16.9) 2 267 
(27.5) 
p<0.01 
2010-2016, n (%) 5 560 
(66.1) 
- - 145 (79.2) 5 415 
(65.8) 
p<0.01 
Table 4. Baseline characteristics for the study population. Individuals with cirrhosis at 
baseline had a concurrent or previous diagnosis of cirrhosis before receiving a diagnosis of 
NAFLD. Differences between baseline variables of individuals with NAFLD with and 
without cirrhosis at baseline were calculated using Wilcoxon rank sum test for continuous 
variables and Fisher's exact test for categorical variables. Abbreviations: COPD=chronic 
obstructive pulmonary disease. 
 
In the competing risk regression analysis, where we treated death from other causes than 
cancer as a competing risk to the event of interest, a diagnosis of any cancer, we found a 
higher risk for cancer in the NAFLD group compared to reference individuals (sub-
distribution HR [sHR] 1.10, 95% CI=1.02-1.20). This pattern was also observed when a 
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diagnosis of HCC was analyzed as the event of interest in the competing risk analysis (sHR 
8.16, 95% CI=5.68-11.75). In male patients with NAFLD (n=4 571), a total of 265 cases 
(5.8%) of cancer was observed during the study, while the 39 712 male reference individuals 
experienced 2 568 cases (6.5%) of cancer. In female patients with NAFLD (n=3 844), a total 
of 262 cases (6.8%) of cancer was observed, while the 31 222 female reference individuals 
experienced 2 148 (6.9%) of cancer. In both male and female patients with NAFLD, the IR 
per 1000 person-years was higher than in their respective reference individuals without 
NAFLD (IR 8.5 vs 8.1 in males, and IR 11.2 vs 9.3 in females). The risk of any cancer was 
slightly higher in female patients with NAFLD compared to female reference individuals, 
than in male patients with NAFLD compared to male reference individuals (aHR 1.18 vs 
aHR 1.26). For HCC, we observed 30 cases (0.7%) in males with NAFLD, compared to 25 
cases (0.1%) in male reference individuals. The IR of HCC per 1000 person-years was 0.9 in 
males with NAFLD, and 0.1 in male reference individuals, corresponding to an aHR of 14.54 
(95% CI=7.35-28.74) for HCC in males with NAFLD compared to male reference 
individuals. In females with NAFLD, we observed 17 cases of HCC (0.4%), compared to 9 
cases (0.0%) in female reference individuals. The IR of HCC per 1000 person-years was 0.7 
in females with NAFLD, and 0.0 in female reference individuals, corresponding to an aHR 
for HCC of 8.74 (95% CI=3.39-22.55) in females with NAFLD compared to female 
reference individuals.  
 
Table 5. Risk of cancer in men and women compared to controls without NAFLD. 
Type of 
cancer 
Incident cases Incidence rate (95% CI) 












Women n=3 844 n=31 222     
All 
cancers 
262 (6.8) 2148 (6.9) 11.2 
(10.0-
12.7) 






HCC 17 (0.4) 9 (0.0) 0.7 (0.4-
1.0) 










32 (0.8) 297 (1.0) 1.3 (0.9-
1.8) 






Kidney 9 (0.2) 32 (0.1) 0.4 (0.2-
0.7) 








Bladder 11 (0.3) 51 (0.2) 0.4 (0.2-
0.8) 






Men  n=4 571 n=39 712     
All 
cancers  
265 (5.8) 2568 (6.5) 8.5 (7.6-
9.6) 






HCC  30 (0.7) 25 (0.1) 0.9 (0.6-
1.3) 











45 (1.0) 352 (0.9) 1.4 (1.1-
1.9) 






Kidney 12 (0.3) 78 (0.2) 0.4 (0.2-
0.7) 






Bladder 26 (0.6) 148 (0.4) 0.8 (0.6-
1.2) 






Table 5. Risk of cancer in male and female subjects with NAFLD compared to reference 
individuals without NAFLD. Cox regression models were performed to estimate hazard 
ratios. The multivariable model is adjusted for diabetes, hypertension, hyperlipidemia and 
chronic obstructive pulmonary disease. Abbreviations: aHR=adjusted hazard ratio, 
HR=hazard ratio, CI=confidence interval, NAFLD=nonalcoholic fatty liver disease, 
PY=person-years. 
 
We found 9 cases (n=0.2%) of kidney cancer in female patients with NAFLD and 32 cases 
(0.1%) in female reference individuals. In male patients with NAFLD, we found 12 cases 
(0.3) of kidney cancer, and in male reference individuals we found 78 cases (0.2%). The IR 
per 1000 person-years for kidney cancer was increased in both female patients with NAFLD 
(IR 0.4 vs 0.1) and male patients with NAFLD (IR 0.4 vs 0.2) compared to their respective 
reference individuals, corresponding to an aHR for kidney cancer of 3.02 (95% CI=1.50-
6.05) in female patients with NAFLD, and an aHR of 1.87 (95% CI=1.02-3.43) in male 
patients with NAFLD. For bladder cancer, we found 11 cases (0.3%) in females with NAFLD 
and 51 cases (0.2%) in female reference individuals, and 26 cases in males with NAFLD 
(0.6%) and 148 cases (0.4%) in male reference individuals. The IR's per 1000 person-years 
for bladder cancer were higher in both females with NAFLD (IR 0.4 vs 0.2) and males with 
NAFLD (IR 0.8 vs 0.5) compared to their respective reference individuals. This corresponded 
to an aHR for bladder cancer of 2.81 (95% CI=1.49-5.31) in females with NAFLD compared 
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to female reference individuals, and an aHR for bladder cancer of 2.43 (95% CI 1.62-3.65) in 
males with NAFLD compared to male reference individuals. In the analyses of risk of 
colorectal cancer, we found the risk to be increased in male patients with NAFLD compared 





The main finding in study 1 was that the risk of developing type 2 diabetes was high in a 
cohort of patients with NAFLD. Indeed, the IR of type 2 diabetes was 18 per 1000 person-
years in our cohort, which is markedly increased compared to the IR of type 2 diabetes in the 
background population in Stockholm, which was reported to be 3.6 per 1000 person-years in 
2010 (143). As previously mentioned, the vast majority of studies investigating the risk of 
type 2 diabetes in patients with NAFLD have used cohorts where patients have received their 
NAFLD diagnoses after undergoing liver US examinations, or have been classified as 
NAFLD using non-invasive models based on liver transaminases and BMI. The different 
diagnostic modalities for identifying NAFLD between our study and most previous studies 
renders direct comparison of results somewhat difficult. The finding of an increased risk of 
development of type 2 diabetes in patients with NAFLD compared to individuals free of 
NAFLD has been reported in the vast majority of studies investigating this subject.  
In one of the largest studies to date, Chen and colleagues investigated the risk of type 2 
diabetes in a cohort of 42 410 Korean individuals with NAFLD (50). In their study, over a 
mean follow-up of 5.8 years, 3 735 (8.8%) of patients with NAFLD went on to develop type 
2 diabetes. This is somewhat lower than the proportion that developed type 2 diabetes in our 
study, which is plausible considering the follow-up in our study was significantly longer 
(mean 18.4 years). As the individuals with NAFLD in the study by Chen and colleagues had 
not undergone liver biopsy, the focus was not - as it was in our study - to assess if any liver 
histological parameters associated with an increased risk of developing type 2 diabetes. The 
Cox regression models we constructed in our study were also stratified on severity of fibrosis, 
with risk factors for developing type 2 diabetes in patients with advanced fibrosis being 
analyzed in a separate regression model. Further, Chen and colleagues included individuals 
without NAFLD in their cohort, thus including NAFLD as an independent variable in their 
Cox regression analysis with type 2 diabetes being the dependent variable. In their unadjusted 
estimates, they reported age, family history of diabetes, hypertension, BMI at or over 27 
kg/m2, cholesterol, elevated triglycerides, HDL, presence of NAFLD, ALP and liver 
transaminases to all be associated with an increased risk of type 2 diabetes. These results are 
somewhat similar to the results from our univariable Cox regression analyses in the group 
with fibrosis stage 0-2, where we found age, elevated triglycerides, hypertension, fat score on 
biopsy, inflammation score on biopsy and NAS to be associated with risk of development of 
type 2 diabetes.  
In the 2006 study by Ekstedt and colleagues, a cohort of patients with biopsy proven NAFLD 
was examined regarding their risk of developing type 2 diabetes (65). The indications for why 
study participants underwent liver biopsies were similar in the study by Ekstedt and 
colleagues and in our study (i.e. due to persistently elevated liver enzymes), which enhances 
comparability between our studies. One important difference between our studies, however, 
was that the patients in the study by Ekstedt and colleagues were not examined regarding 
signs of type 2 diabetes at baseline. If the included patients had a diagnosis of diabetes 
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already ascertained at baseline, which was the case in 8.5% of the cohort, this was noted. The 
other patients were not examined with a test of fasting glucose at baseline, thus the baseline 
prevalence of type 2 diabetes in the study by Ekstedt and colleagues was unclear. It can be 
noted, though, that prevalence of disorders related to the metabolic syndrome was 
comparably high in the baseline cohort, with 56% being overweight, 29% obese, 72% 
hypertensive, and 57% suffering from hypertriglyceridemia. It is therefore plausible that the 
baseline prevalence of type 2 diabetes was higher than the ascertained 8.5%. At the time of 
the follow-up assessment, 88 of the 104 from the original study cohort (n=129) who were still 
alive chose to participate. At follow-up, 37% of participants had received a diagnosis of 
diabetes prior to the follow-up visit, and an additional 16% were diagnosed at the follow-up 
visit. Further, 20% were diagnosed with impaired glucose tolerance at the follow-up visit. 
Thus, in total, 78% of the participants that took part in the follow-up assessment had either 
impaired glucose tolerance or diabetes. The authors note that 71% of the patients with 
baseline NASH that attended follow-up had diabetes, compared to 46% of the patients 
without baseline NASH, and that the difference in follow-up prevalence of diabetes was 
found to be statistically significant. This finding is in line with the results from our study, 
indicating that histological severity of NAFLD could be of prognostic value when identifying 
risk of type 2 diabetes. However, the relatively small size of these histology-based cohorts 
did not allow for full adjustment of plausible confounders, why future studies in this field 
needs to be appropriately sized. Another note is that liver histology is unlikely to be a 
clinically valuable predictor of incident diabetes per se, given its invasive nature. 
 In the large meta-analyses published by Mantovani and colleagues in 2018, a total of 296 
439 participants, out of which almost one third (30.1%) had NAFLD, from 19 different 
studies were included. Reflecting the active NAFLD research in Asia, a majority of studies 
included in the meta-analysis were performed on Asian cohorts. As the quality of the studies 
included varied, the authors performed a sensitivity analysis where they included only studies 
of in which risk-estimates had been adjusted for important confounders. In this sensitivity 
analysis of high quality studies, the pooled HR for risk of type 2 diabetes in NAFLD 
compared to reference individuals without NAFLD was 1.85 (95% CI=1.47-2.22). In an 
attempt to investigate if severity of NAFLD is of importance in assessing the risk of type 2 
diabetes, the authors performed separate examinations of the four studies included in the 
meta-analyses that had reported severity of NAFLD, either from classification by liver US or 
by NFS. In the three studies where severity of NAFLD was assessed by liver US, an HR of 
2.15 (95% CI=1.57-70) for risk of type 2 diabetes was reported, and in the one study where 
severity was assessed by the NFS, an HR of 4.74 (95% CI=3.54-5.94) was reported. While 
these estimates are derived from a small number of studies using diagnostic tools that are not 
considered gold standard, they indicate that severity of NAFLD is of importance when 
assessing risk of type 2 diabetes in patients with NAFLD. This conclusion is supported by the 
results from our study, where we were able to test this hypothesis using the gold standard 
diagnostic modality, liver biopsy, for ascertaining disease severity. Thus, our results 
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combined with results from previous studies indicate that physicians should take extra careful 
consideration in assessing the risk of type 2 diabetes in patients with more severe NAFLD. 
In study 2, our main finding was that patients with type 2 diabetes are at a higher risk of 
severe liver disease than matched controls without diabetes after a median of 7.7 years of 
follow-up. Previous studies on the risk of different forms of severe liver disease in patients 
with diabetes have repeatedly reported an increased risk compared to patients without 
diabetes. As the diagnostic coding for diabetes previously did not separate between type 1 
and type 2 diabetes, many of the earlier studies on risk of liver disease in patients with 
diabetes were not able to distinguish between type 1 and type 2 diabetes in their cohorts. In 
the previously mentioned studies from 2002 and 2004, El Serag and colleagues investigated 
the risk of acute hepatic failure (75) and HCC (66) in a cohort of more than 800 000 military 
veterans in the US, out of which 173 643 patients had a discharge diagnosis of diabetes 
between 1985 and 1990, and reported and association to an increased risk of both conditions 
(aHR 1.43 for acute hepatic failure, aHR 2.13 for HCC) in patients with diabetes compared to 
individuals without diabetes. These results are supported by our study, where we were able to 
differentiate between type 1 and type 2 diabetes and included a more diverse cohort (98% of 
participants in the studies by El-Serag and colleagues were male).  
In a more recent study on the risk of liver disease in patients with type 2 diabetes, Wild and 
colleagues used the Scottish National Diabetes Registry and Scottish hospital admission 
records, cancer records and causes of death records to identify liver disease in the Scottish 
population. During a follow-up of 1.8 million person years in patients with type 2 diabetes, 
and 24 million person years in reference individuals free of diabetes, cases of several 
different types of liver disease were identified. Alike the findings in our study, Wild and 
colleagues reported an independent association between type 2 diabetes and risk of HCC in 
both men (rate ratio 3.36, 95% CI=2.97-3.81) and women (rate ratio 3.55, 95% CI=3.02-
4.17), adjusted for age and socio-economic status. In a recent meta-analysis on the 
association between components of the metabolic syndrome and severe liver disease by Jarvis 
and colleagues, published in 2020, study 2 in this doctoral thesis was included. As is the case 
in many meta-analyses, the heterogeneity between studies included in the study by Jarvis and 
colleagues was considerable (I2=99%), which motivates caution when considering the 
reported pooled estimates. Reporting results from studies that looked at both fatal and non-
fatal severe liver disease in patients with no other liver disease etiology than NAFLD, an 
association between type 2 diabetes and risk of severe liver disease was identified (HR 2.25, 
95% CI=1.83-2.76). The results from this meta-analysis (which included our own study) is in 
line with our findings.  
One aspect on the risk of liver disease patients with type 2 diabetes that we analyzed in study 
2, that was not reported in most previous studies of risk of liver disease in patients with type 2 
diabetes, was the risk difference among different age groups. We found the absolute risk of 
severe liver disease in patients with type 2 diabetes under 50 years of age to be low. In the 
perspective of potentially formulating a more concise screening strategy, it can be argued that 
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information on the difference in risk across different age groups is highly valuable. Our study 
differs from previously published studies on the topic in several ways. First, our cohort is 
population-based. Second, we were able to differentiate between type 1 and type 2 diabetes 
Finally, we used a composite outcome of severe liver disease rather than single diagnoses - or 
mortality from single diagnoses. For health care providers, the results from study 2 can 
increase the awareness of the risk of severe liver disease in the large patient population with 
type 2 diabetes and increase the probability of earlier detection. 
In study 3, the main findings were the high prevalence of elastography-defined NAFLD and 
elevated liver stiffness in patients with type 2 diabetes, and that an improvement in glycemic 
control after a 4-day personalized treatment program was associated with an improvement of 
hepatic steatosis. As we investigated a comparably small sample of study participants, the 
frequencies of NAFLD and elevated liver stiffness should be interpreted with caution. 
However, the observed results indicate a significant prevalence of clinically relevant liver 
disease in this cohort. In the previously mentioned study by Kwok and colleagues, where the 
prevalence of increased CAP and elevated liver stiffness in a cohort of patients with type 2 
diabetes were evaluated, increased CAP was found in 72.8% of patients and elevated liver 
stiffness was found in 17.7% of patients. In our study we found a baseline prevalence of 
increased CAP of 76%, and a baseline prevalence of elevated liver stiffness of 24.2%. The 
similarities between our results and the results reported in the study by Kwok and our study 
indicate that the results we observed are somewhat representative of the general frequency of 
NAFLD and elevated liver stiffness in patients with type 2 diabetes. However, some 
significant differences between our studies should be noted. On the one hand, our cohort 
consisted of patients with difficult-to-treat type 2 diabetes, whereas the cohort in the study by 
Kwok and colleagues consisted of patients who were recruited to the study while undergoing 
screening for complications from type 2 diabetes. This difference would probably result in a 
higher prevalence of NAFLD and elevated liver stiffness in our cohort. On the other hand, the 
cut-off used for defining steatosis grade 1 in the study by Kwok and colleagues was 233 
dB/m, whereas we used a cut-off of 268 dB/m. The broader classification of NAFLD in the 
study by Kwok and colleagues meant that individuals whom in our study would have been 
identified as not having NAFLD were classified as having NAFLD, thus increasing the 
prevalence in the study by Kwok and colleagues. A reasonable synthesis of these findings 
would be that the prevalence of NAFLD and advanced fibrosis increases with the severity of 
diabetes and insulin resistance.  
The observation that a personalized treatment program aimed at improving metabolic control 
is associated with reduction in hepatic steatosis is in line with previously reported effects of 
diet, exercise and some anti-diabetic medications on NAFLD. The clinical implications of 
these findings could be that physicians treating patients with type 2 diabetes and improving 
their glycemic control can also improve the liver health of the patients. However, long-term 
effects regarding liver-related outcomes and mortality from this type of personalized 
treatment program in patients with type 2 diabetes remains uncertain. 
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In study 4, the main finding was that NAFLD was associated with an increased risk of cancer. 
The risk of HCC was comparably high, while the risk of other forms of cancer was only 
slightly elevated. Comparison to results from previously published studies is somewhat 
complicated by differences in the characteristics of study cohorts and differences in 
confounders adjusted for in multivariable models. In the 2018 study by Kanwal and 
colleagues, where an increased risk of HCC compared to patients without NAFLD was found 
primarily in patients with NAFLD and cirrhosis, for example, the diagnosis of NAFLD was 
made by identification of consecutively elevated ALT levels, and the cohort consisted of a 
majority of male subjects. We found a higher IR of HCC in patients with NAFLD but without 
cirrhosis than was reported in the study by Kanwal and colleagues. One explanation for this 
could be that we included only patients with NAFLD that had come in to contact with 
specialized care, and therefore belonged to a higher risk category than the patients in the 
study by Kanwal and colleagues, or that cirrhosis is under-coded in the NPR.  
The recent results from a study by Simon and colleagues on Swedish patients with biopsy-
proven NAFLD indicate a significant increase in risk HCC compared to individuals without 
NAFLD (aHR 1.27, 95% CI=1.18-1.36). These results are rather similar to results from study 
4, in which we calculated an aHR for patients with NAFLD of 1.22 (95% CI=1.12-1.33) for 
any cancer compared to matched reference individuals. Regarding risk of HCC, Simon and 
colleagues reported an increased risk in patients with NAFLD (aHR 17.08, 95% CI=11.56-
25.25), while we observed an aHR for HCC of 12.18 (95% CI=7.15-20.79) for patients with 
NAFLD. One would expect our results to fairly similar, as the cohorts of patients that we 
studied in large part probably consists of the same patients (Swedish individuals who have 
received a diagnosis of NAFLD in specialized care during the last decades). Important 
differences between the study by Simon and colleagues and study 4 include the diagnostic 
modality, where Simon and colleagues included only patients who had undergone liver 
biopsy, and therefore likely had more severe liver disease. This is reflected in the somewhat 
lower risk-estimates in our study.  
In terms of clinical implications, the results in study 4 together with previous studies indicate 
that screening for cancer, except for HCC, in patients with NAFLD is unlikely to be 
necessary due to the low absolute risk of cancer. Regarding screening for HCC, it is likely of 
use in the group of patients with NAFLD with the highest risk of HCC. How to define this 
group, and how to outline a potential screening program, will be an area of future research. 
The results from our study indicates that the elevated risk of HCC is present in some patients 
with NAFLD even if they do not have cirrhosis. 
5.1 LIMITATIONS 
All four studies included in this thesis were of observational design. As the observational 
design lacks randomization and therefore inherently carries residual confounding, 
conclusions regarding causality cannot be drawn from generated results. Even in studies 
where reference individuals free of the exposure of interest are included, as was the case in 
studies 2 and 4 in this thesis, one must be careful to only draw conclusions about associations 
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between exposures and outcomes, and not about causal mechanisms. While causal inference 
is usually not possible from observational studies, observed results can still be of value both 
in clinical settings, in construction of screening strategies and in generating hypotheses ample 
for testing in randomized trials. Further, some hypotheses are not testable in a randomized 
setting. It would not be possible, for example, to randomize one group of study participants to 
develop type 2 diabetes and one group to remain free of diabetes and then examine the effects 
on development of severe liver disease. This ties in to one of the most fundamental aspects of 
science; the idea that the objective of scientific endeavor is not to prove one’s hypothesis, but 
to try to refute it. In a scientific sense, there is no way to "prove" a hypothesis. Since no 
experiment in science can be carried out in a perfect, limitation-free manner, all observed 
results and subsequent conclusions carry caveats. Thus, it is inaccurate to speak in terms of 
"scientifically proving" something, or that something has been "scientifically proved". While 
a hypothesis cannot be proved, it can have more or less support. Where we as scientists and 
medical professionals choose to draw a line and postulate that a hypothesis has been 
researched enough, and has enough support to implemented in clinical practice, is a question 
that requires careful consideration on a case-by-case basis. The potential benefits of 
implementing a new routine in clinical practice must be weighed against the risk of acting on 
the hitherto generated evidence. The scientific mechanism of probabilistic reasoning has to be 
communicated in a pedagogical way to the general public, to policy makers, and - in the case 
of medical research - to patients that will be affected by implementing scientific findings in 
clinical practice. Overstating the certainty of one’s findings in medical science could, in a 
worst case scenario, put patients at harm. Further, it could undermine the public trust of 
science. Thus, understanding and clarifying limitations in one's studies is a fundamental 
aspect of sound scientific research. 
The inclusion of study participants using national, population-based registries has both 
benefits and drawbacks. The fact that all individuals in the population of Sweden, regardless 
of ethnic background, socioeconomic status, sex or place of living are included in the 
registries benefits the diversity of the generated cohorts. In turn, the diversity of the cohorts 
benefits the external validity of studies performed on the population-based cohorts. The 
reliance on patient registries for constructing cohorts confers a selection bias in that an 
individual has to come in contact with healthcare to be registered. If an individual suffers 
from NAFLD, the disease can go unrecognized for long periods of time if no examination is 
performed. The probability of inclusion in the registry in question is thus dependent on the 
propensity of the individual with the disease to seek healthcare (either for a general check-up 
or for evaluation of some specific symptom). The propensity of the individual to seek 
healthcare can be associated with a number of confounding factors that introduces a bias into 
generated risk-estimates. A similar impediment to external validity was present in study 3, 
where we investigated a cohort of patients with type 2 diabetes who enrolled in a 4-day 
program aimed at improving glycemic control and other metabolic parameters. As the referral 
of their primary care provider meant that the patients had to take active part in care provided 
at a specialist center in a university hospital, a selection was likely present were some patients 
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that were not inclined to take a more active part in the treatment of their condition did not 
enroll in the program and were thus left out of our cohort. Another limitation of using 
registries to study a disease like NAFLD is the internal validity, due to the disease being 
notoriously under-recognized in the registries. The under-recognition of NAFLD in the 
registries likely has several reasons. First, knowledge of the diagnosis is lacking in the 
broader spectrum of healthcare personnel, leading to a low likelihood of detecting the disease 
in its most common, non-symptomatic form. Second, easy to use, economically feasible and 
reliable diagnostic tools are lacking. Hence, even as knowledge about NAFLD is increasing 
among health care personnel, the diagnostic difficulties hamper real-world diagnosing in 
patients. The resulting effect of this misclassifications in studies using registry-based cohorts 
will most often be falsely low risk-estimates, as the effect is diluted by many individuals with 
NAFLD that are wrongly included as reference individuals. 
In study 1, the size of the cohort was a limitation in that it possibly was not large enough to 
detect all true associations between exposure (histological features of NAFLD) and risk of 
developing the outcome (type 2 diabetes). Further, as identification of development of type 2 
diabetes in a study participant is reliant either on the disease producing symptoms inferring 
the patient to seek healthcare, or on detection of abnormal blood glucose levels during a 
general health check-up, it is likely that some patients actually did develop type 2 diabetes 
during follow-up but went undiagnosed. This could potentially have led to both falsely low 
and falsely high risk-estimates. Another limitation in study 1 was the amount of missing data 
of baseline variables that we deemed important to include in Cox regression analysis. 
Namely, baseline documentation on fasting glucose and triglycerides were missing in 89 
(22%) and 145 (37%) patients, respectively. This limitation could also introduce bias which 
could lead to both falsely low and falsely high risk-estimates. When participants are included 
due to having undergone some type of diagnostic test, it is paramount to consider the 
indications for the test, as this might introduce an important selection bias. The individuals 
included in study 1 had undergone liver biopsies due to persistently elevated liver 
transaminases. This compromises the external validity of study 1, in the sense that many 
patients with NAFLD does not have abnormal liver transaminases, and that conclusions 
drawn in the study therefore might not be relevant for the large population of patients with 
NAFLD and normal liver transaminases. 
In study 2, the relatively short follow-up time was a limitation. As patients were followed for 
a median of 7.7 years, and severe liver disease as previously mentioned can develop over 
decades, we most likely did not have enough time to fully observe a potential association 
between type 2 diabetes and development of severe liver disease. This limitation would 
generate a falsely low risk-estimate. A further limitation in study 2 is the probable 
misclassification of patients with undiagnosed type 2 diabetes as reference individuals free of 
diabetes. As is the case with NAFLD, type 2 diabetes is a disease that can be present in a 
patient for long time periods with no apparent symptoms. Thus, it is likely that some 
individuals included in study 2 as reference individuals in fact suffered from type 2 diabetes. 
This would lead to a dilution of the observed hypothesized effect of type 2 diabetes on the 
 
48 
risk of developing severe liver disease, and falsely low risk estimates. Another source of 
misclassification is that a substantial number of participants, both patients with type 2 
diabetes and reference individuals, included in study 2 likely had an alcohol intake which 
could cause liver disease without having received a diagnosis of alcohol abuse. As we were 
aiming to investigate the effects of type 2 diabetes - and not excessive alcohol consumption - 
on liver disease this could reduce the internal validity of our study. It is not entirely obvious, 
though, that this misclassification would differ between exposed individuals and reference 
individuals, which would have made it more problematic. In the Cox regression analysis of 
risk factors for development of severe liver disease, we did not include reference individuals 
as we only had data on age, sex and living location on these individuals. Had we been able to 
obtain more baseline variables for the reference individuals free of diabetes, the conclusions 
we were able to draw from the study regarding specific risk factors for severe liver disease in 
patients with type 2 diabetes could have been more solid.  
Participants in study 3 were included from group of patients that had been referred to an 
endocrinology clinic by primary care providers as they found it difficult to manage the 
participants’ disease course. This limits the generalizability of the conclusions study 2, as the 
results are not generalizable to patients whose metabolic control is successfully managed in 
the primary care setting. Further, the fact that a number of individuals declined to participate 
in the study could introduce a selection bias as these individuals possibly differ from the 
individuals that chose participate. The individuals that did not participate in the study could, 
for example, have more severe disease. If this is the case, then we likely observed falsely low 
estimates of NAFLD and elevated liver stiffness in the cohort. As in study 1, the size of the 
cohort in study 3 warrants caution when interpreting the results. In all, 91 patients were 
enrolled in the study at baseline. Due to technical difficulties performing the transient 
electrography examination, software malfunctioning, and loss to follow-up, the number of 
participants with good quality baseline and follow-up measurements of steatosis was reduced 
to 61 patients, out of which 39 had NAFLD at baseline. With this relatively small number of 
individuals in the study cohort, the risk of obtaining results that makes one accept the null 
hypothesis when in fact the alternative hypothesis is correct (i.e. type 2 error) is increased. 
Another limitation to consider in study 2 is related to the technical difficulties of performing 
the transient electrography examination in severely obese patients. As this can be more 
difficult, a large proportion of failed examinations occurred in severely obese patients, thus 
skewing the cohort towards less obese, and likely metabolically more healthy patients. The 
observed 76% baseline prevalence of NAFLD and 24.2% baseline prevalence of kPa values 
indicating significant fibrosis were, therefore, likely falsely low estimates. 
In addition to the above-mentioned limitation of under-diagnosing of NAFLD in study 4, a 
further limitation was the inclusion of patients with NAFLD from the NPR. As the NPR does 
not include patients that are followed in primary care, and this is where the overwhelming 
majority of patients with NAFLD are followed, we likely had a selection of comparably 
severe cases of NAFLD, who had for some reason encountered specialist care, in our study. 
However, the relatively low prevalence if cirrhosis argues against selection bias as a major 
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threat to the study’s results. As in study 2, even though we did not include any individuals 
who had received a diagnosis of alcohol-related liver disease or alcohol abuse, we might have 
included individuals with liver disease due to alcohol-related liver disease. In the Cox 
regression models, we incorporated four baseline variables deemed to be confounders of 
interest: diabetes, COPD, hypertension and hyperlipidemia. To identify if these covariates 
were present at baseline we used the NPR. As earlier alluded to, these diagnoses can be 
present in patients for long periods of time, and only detected and diagnosed when the patient 
encounters healthcare. Further, they are only entered into the NPR when a patient encounters 
specialist care. Thus, it is highly likely that we under-diagnosed these conditions in our study 





The main findings from the four studies included in this doctoral thesis - and the subsequent 
conclusions generated from these findings - can be summarized as follows: 
- The risk of type 2 diabetes is elevated in patients with NAFLD. Higher stage of fibrosis on 
liver biopsy associates with higher risk of type 2 diabetes. For patients with NAFLD but little 
fibrosis, higher amount of fat on liver biopsy associates with higher risk of type 2 diabetes. 
- The risk of severe liver disease is increased in patients with type 2 diabetes compared with 
matched controls from the background population. While this increase in risk of severe liver 
disease is observed across all age groups of patients with type 2 diabetes, patients under 50 
years of age have a low absolute risk. Among patients with type 2 diabetes, male sex, older 
age, smoking, higher BMI, presence of hypertension, and lower GFR is associated with an 
increased risk of severe liver disease. 
- Patients with type 2 diabetes deemed difficult to treat by a primary care physician have a 
high prevalence of NAFLD and elevated liver stiffness, indicating presence of significant 
fibrosis. In these patients, reduction in fasting glucose achieved by a four-day personalized 
treatment program is associated with a decrease in hepatic steatosis during a three-month 
period. 
- In the general population in Sweden, a diagnosis of NAFLD is associated with a somewhat 
increased risk of developing cancer. While a slight association between NAFLD and risk of 
bladder, kidney and uterine cancer, and between NAFLD and risk of colorectal cancer in men 
is present, the strongest association is seen for NAFLD and HCC. The results argue against 




7 FUTURE RESEARCH 
Several important questions regarding the interaction between type 2 diabetes and NAFLD, 
and the optimal clinical care of the large populations with these conditions, remain to be 
answered. One of the more pressing issues, which we've partly aimed to address in this 
doctoral thesis, is how to construct the optimal screening strategy for identification of 
NAFLD in patients with metabolic syndrome or type 2 diabetes. In Sweden, the absolute 
majority of with type 2 diabetes is managed in primary care. As previously mentioned, the 
majority of patients with NAFLD will not go on to develop end-stage liver disease. 
Nonetheless, the size of the patient population likely means that even if only a fraction of 
patients with NAFLD eventually develop severe liver disease, this will eventually place a 
heavy burden on an already strained health care system. Thus, a concise strategy 
implemented on the primary care level for identifying patients with a high risk of developing 
severe liver disease would likely be of great individual, systemic and - in the long run - 
societal benefit. As made clear by the last few decades of research on this topic, translating 
results from scientific studies on the matter into the desired strategy for finding high risk 
patients is very difficult. Using a screening strategy that is too inclusive would result in 
excess number of patients being referred from primary care to specialist centers, draining 
much needed resources quickly. Using a screening strategy that is too selective, on the other 
hand, would result in misclassification of high-risk patients as low-risk patients, potentially 
resulting in high levels of morbidity and mortality that could have been prevented. To clarify 
this question, future studies will need a number of high-quality characteristics compared to 
previous studies. First, capture rate of both exposure and outcomes will have to be higher. 
That is, NAFLD, as well as other traits related to the metabolic syndrome, have to be 
diagnosed with a higher accuracy in future study cohorts than what has been achieved to date. 
The higher diagnostic accuracy could be achieved either through a higher use of high-quality 
diagnostics already available (such as liver biopsy), or by using new diagnostic methods. 
Given the amount of resources demanded by the currently available high-quality diagnostic 
methods, some combination of these two paths will likely be needed.  
Likewise, while potentially not as big of a problem in previous studies, the outcomes of 
severe liver disease will need to be identified with higher accuracy. Further, as both type 2 
diabetes, NAFLD, and potential end-stage complications of NAFLD develop over extended 
time periods, sufficient follow-up will be of key importance in future studies of what 
characterizes high-risk patients. As mentioned previously, hitherto performed studies on both 
the risk of type 2 diabetes in patients with NAFLD, as well as studies on the risk of 
development of severe liver disease in patients with type 2 diabetes, have mostly had follow-
up times spanning from five to ten years. Sufficient follow-up in the context of these 
conditions would likely require studies following cohorts of patients for several decades, 
reflecting the time it takes for a patient to (potentially) pass through the different stages of 
disease progression. Parallel to observational studies, further mechanistic studies on 
biochemical pathways and causal associations will most likely be paramount in detangling 
how type 2 diabetes, NAFLD, and severe liver disease interact. 
 
54 
The question of how treatment of a patients type 2 diabetes affects the often co-existing 
NAFLD also requires further research. With conditions that are so likely to co-exist, 
consideration has to be given to the possibility that treatment of one of the two condition 
worsens the other. Likewise, the frequent co-existence of type 2 diabetes and NAFLD hints 
that they are caused by similar mechanisms, and therefore possibly best treated with similar 
pharmacological and life-style strategies. Thus, further elucidating which treatments of type 2 
diabetes that are potentially beneficial also for treating NAFLD will likely be a continued 
focus of future studies. 
As with previously described regarding studies on the interactions between NAFLD and type 
2 diabetes, future studies on the link between NAFLD and cancer will require higher capture 
rates of both exposures and outcomes, as well as longer follow-ups. Given the relatively low 
risk-estimates in previous studies examining risk of non-HCC cancer in patients with 
NAFLD, future studies will likely focus on clarifying how to distinguish patients with 
NAFLD who have a high risk of HCC from patients with NAFLD who a low risk of HCC. 
Again, this will be a joint effort between epidemiologic research and biochemical research 
aimed at finding mechanistic, causal pathways. Results from current studies of treatments for 
NAFLD are often evaluated on histological end-points. As medications are approved and put 
to use in the large patient population with NAFLD, subsequent studies with longer follow-up 
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